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Abstract 
Objectives: We performed a systematic review of the literature to evaluate the potential benefits and 
harms of a screening program for bladder cancer in a targeted, primary care population of men over age 
50.  We sought to answer five Key Questions deemed necessary to make a recommendation for or against 
screening: 1) Does screening for bladder cancer lead to decreased morbidity or mortality?, 2) Do potential 
screening modalities have appropriate test characteristics to warrant their use as a screening test?, 3) Does 
earlier treatment of early stage reduce morbidity and mortality more than later treatment?, 4) What are the 
harms of screening?, and 5) What are the harms of a full urologic workup? 
Methods: For each Key Question, we searched MEDLINE, EMBASE, and the Cochrane database of 
reviews and trials for studies published in English between 1982 and 2010.  Data was extracted from 
articles that met our eligibility criteria by two independent observers.  Study quality was assessed using 
criteria adapted from the US Preventive Services Task Force, and results were synthesized qualitatively. 
Results: Two studies were identified that performed a trial of screening and reported long-term mortality 
results.  A mortality benefit of screening was found in one study, but both were poorly designed and 
definitive conclusions cannot be drawn.  Eleven studies of diagnostic accuracy for potential screening 
tests were identified that met our eligibility criteria.  None of the six examined tests (hemoglobin dipstick, 
urine cytology, NMP22, BTA stat, ImmunoCyt and Urovysion FISH) were found to have an adequate 
combination of sensitivity and specificity for use as a screening test, and overall study quality was poor.  
We found no studies examining the effects of earlier treatment versus later treatment of early stage 
bladder cancer, and no studies examining the harms of screening.  Harms identified for a urologic workup 
include urinary tract infection and sexual dysfunction from cystoscopy, and heavy doses of radiation from 
imaging studies. 
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Conclusions: The available evidence is not sufficient to recommend screening for bladder cancer in a 
primary care population.  There is a need for a widespread, randomized controlled trial examining both 
the benefits and harms of a potential screening program. 
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Introduction 
Overview 
Urothelial cell carcinoma of the bladder is the most commonly diagnosed malignancy of the 
urological system.  The American Cancer Society estimates that there will be 70,980 new cases diagnosed 
in 2009, with 52,810 of these cases occurring in men and 18,170 occurring in women (1).  The ACS 
obtained these estimates using incidence data from the SEER (Surveillance, Epidemiology and End 
Results) program, a cancer registry that estimates nationwide rates.  Cancer registration is incomplete in 
some states, and SEER data is based on rates that are three to four years old. These estimates are adjusted 
using a spatiotemporal model and considered to be a good indicator of overall disease burden.  
Bladder cancer is the fourth most common malignancy in males and the eighth most common in 
females in the United States.  The incidence of urothelial cell carcinoma was estimated to be 21 per 
100,000 persons in the United States in the year 2000 by the CDC (2).  According to calculations by the 
World Health Organization bladder cancer accounted for 109,000 Disability Adjusted Life-Years 
(DALY‟s) in the United States, Canada and Cuba (America A region) in the year 2000 (3), comprising 
1.9% of DALY‟s due to malignant neoplasms in that region. Calculations of DALY‟s by WHO should be 
viewed in light of the quality of cancer outcome data available in the particular regions being examined, 
and data from the America A region should be considered comparably reliable to other WHO regions.  
Additionally, ACS estimates that there will have been 14,330 deaths due to bladder cancer in 2009, with 
10,180 occurring in men and 4,150 occurring in women (1).  While the number of bladder cancers 
diagnosed in the United States increased by more than 50% from 1985 to 2008, mortality decreased from  
5.1/100,000 to 4.0/100,000 among males and from 1.8/100,000 to 1.5/100,000 among females from 1970-
2000, according to WHO data (4).   
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A screening program in the US directed at the subpopulation at greatest risk, males over age 50, 
could potentially reduce this substantial mortality.  Using conservative estimates of attributable risk for 
disease due to age and gender,
1,4
 we calculate that nearly 80% of cases occur within this subgroup.  Death 
due to bladder cancer is highly dependent on muscle invasion, and no studies thus far have demonstrated 
a link between age or gender and grade of disease at diagnosis.  Therefore, the percentage of deaths due to 
bladder cancer occurring in the group of men over the age of 50 would also be expected to approach 80%. 
Disease characteristics 
Morbidity and mortality of urothelial cell carcinoma is highly dependent on the degree of muscle invasion 
at diagnosis.  Pelucchi and colleagues observed through a systematic review of clinical outcomes 
literature that almost 95% of bladder malignancies are classified as Transitional Cell Carcinomas (TCCs); 
these cancers exhibit a distinctly dichotomous behavior pattern (5).  Approximately 55% of newly 
diagnosed TCCs are low- or moderate-grade superficial lesions, whereas 45% of newly diagnosed lesions 
are high-grade (6).  These two categories of TCCs tend to behave in very different manners.  In a 
multivariate analysis of 1529 patients with superficial bladder cancer, none of the patients with low-grade 
cancer died of the disease (7).  Additionally, none of the tumors in this group progressed to more serious 
disease.  On the other hand, 9.5% of patients with high-grade tumors eventually died of the disease, and 
an additional 15% had progression.  This indicates that the vast majority of mortality risk belongs to those 
in the high-grade category.   
While low- to moderate-grade lesions frequently recur after resection, they almost never invade 
muscle; this is illustrated by the fact that only 2% of grade 1 lesions do so (8).  In contrast, 11% of grade 
2 lesions and 25% of grade 3 lesions will invade muscle.  The high rate of recurrence among low-grade 
tumors, however, has led the American Urological Association to recommend lifelong surveillance, with 
cystoscopy performed every three months for the first two years after tumor resection (9).  This 
recommendation is based on relatively weak evidence, namely a small number of case-control studies.  
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No randomized controlled trials have been performed to evaluate the most effective surveillance schedule.  
On the other end of the spectrum, 60% of newly diagnosed high-grade lesions are muscle invasive at the 
time of diagnosis, and those that had not yet invaded muscle will later do so in 45% of cases (8).  For a 
potential screening program to be effective, these high-grade tumors must be found via screening before 
they have progressed to muscle invasion. 
The management of bladder cancer also entails a significant financial burden.  Because of the 
need for lifetime surveillance to detect recurrences, the cost per patient from diagnosis to death is the 
highest among all cancers, as calculated by Bottemann et al. through a comprehensive review of bladder 
cancer economic literature (10).  Lifetime costs range from $96,000 to $187,000 in 2001 dollars in the 
United States.  Bladder cancer accounts for almost $37 billion (2001 values) in direct costs to the US each 
year, making it the fifth most expensive cancer overall in terms of total medical care expenditures.  Total 
expenditures are especially impressive when considering the relatively low prevalence of the disease.  
The review by Bottemann is limited by the small number of economic papers devoted to bladder cancer 
since 1990; however, it gives us a general idea of the substantial economic burden of this disease. 
Risk factors 
The diagnosis of urothelial cell carcinoma is disproportionately weighted towards older individuals and 
males.  The incidence of the disease ranges from 3 to 4 times higher in men than in women in the United 
States (1).  This is thought to be due to higher levels of exposure to environmental risk factors in men, 
namely cigarette smoke and occupational hazards leading to exposure to aromatic amines (11).   
Additionally, bladder cancer is typically diagnosed in older individuals in the US.  The median 
age at diagnosis is 69 in men and 71 in women, according to SEER data examined by the ACS (1).  
Incidence increases with age; the incidence in men age 65-69 of 142 per 100,000 males rises to 296 per 
100,000 males in those 85 and older (5).  Racial disparities for presentation and bladder cancer-specific 
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mortality also exist.  Scosyrev and colleagues found that while incidence for white males is roughly twice 
the incidence for African American males, African Americans are more likely to present with muscle 
invasive disease (12).  Furthermore, black patients experience higher mortality, with a hazard ratio for 
death of 1.71 for the first 1-2 years after diagnosis (12).  However, this ratio decreases to 1.26 when 
adjusting for grade of disease at presentation.  Scosyrev and colleagues obtained these estimates of risk 
from analysis of the SEER database.  While these data may be subject to inaccuracies in pathological 
diagnoses and causes of death due to variance in pathological technique and death certificates between 
institutions, it is not likely that these inaccuracies were distributed unequally between races. 
An estimated 50-80% of bladder cancers are directly attributable to environmental risk factors,
14-
18
 the most prominent of which in the United States is exposure to cigarette smoke.  Estimates of the 
fraction of risk attributable to these risk factors should be interpreted with caution, as they are almost 
entirely based on analysis of case-control studies.  According to a CDC analysis of the 2005 National 
Health Interview Survey (NHIS), 20.9% of US adults were current smokers in that year (13).  23.9% of 
men in the survey were smokers, compared to 18.1% of women.  Overall smoking prevalence was 24.4% 
for those age 18-24, 24.1% for those age 25-44, 21.9% for those age 45-64, and 8.6% for those over 65.  
In a pooled analysis of 11 case-control studies, Brennan and colleagues estimated that the odds ratio of 
disease for those who had smoked less than 10 years was approximately 2, whereas those who had 
smoked for greater than 40 years had an odds ratio in excess of 4 (14).   
A dose-response relationship has been observed between the number of cigarettes smoked per 
day and bladder cancer, up to a threshold of 15-20 cigarettes per day, after which no increased risk is 
observed (14).  This meta-analysis has the advantage of being able to demonstrate a dose-response 
relationship that the individual case-control studies were too small to detect, although again results should 
be interpreted with caution since case-control studies alone were used as evidence.  Although this analysis 
did include case-control studies that differed in the selection of controls (hospital vs. population-based), a 
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stratified analysis by control group type did not significantly affect results.  Brennan et al. estimated the 
proportion of all bladder cancer cases attributable to smoking to be 66% among all men and 73% for men 
younger than 60 (14).  30% of cases in women are attributable to smoking.  Using the 2009 American 
Cancer Society projections for disease, this equates to 35,000 cases in men and 5,000 cases in women due 
to smoking in the year 2009 (1).  Smoking cessation is associated with an immediate decrease in risk, 
with a 30% decrease in risk of disease in the first one to four years after quitting (14).  This decrease rises 
to 60% after 25 years of smoking cessation; however, risk never reaches the level of decreased risk for 
never-smokers.   
In addition to cigarette smoke, there are several well-characterized occupational risk factors for 
the development of urothelial cell carcinoma.  Jung and colleagues estimated that industrial exposure to 
aromatic amines is responsible for 10 to 20 percent of bladder cancer development (15).  Using the 2009 
projections for disease by the American Cancer Society, that would equate to 7,000 to 14,000 cases in 
2009 due to occupational exposure (1).  Industries that have been linked with an increased risk include the 
metal, leather, rubber, paint, diesel, textile and dye industries (16).  The elevation of risk in each such 
industry varies widely based on the level of exposure to these particular carcinogenic compounds.  For 
example, in a compelling meta-analysis of 35 studies examining the relationship between diesel exhaust 
and bladder cancer, Boffetta and colleagues found that the summary relative risk was 1.13, with a 
confidence interval that included the null value (17).  In contrast, the British investigator Robert Case 
found in 1954 that substantial exposure to aromatic amines in the dye industry produced a relative risk of 
nearly 200 for those with substantial exposure compared to those with no exposure (18).  Due to the wide 
variety of industries linked with bladder cancer development, we did not find enough information to 
accurately estimate the size of this subpopulation at risk. 
Knowledge of strong risk factors for bladder cancer could potentially be useful in the 
development of a specific protocol, particularly in terms of defining the target group.  Since those with 
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high-grade disease are those at greatest risk of progression to muscle invasion, and thus death, 
identification of specific risk factors associated with high-grade tumors would be of great use.  For 
instance, if smoking more than two packs of cigarettes a day were strongly associated with high-grade 
disease then it is possible that only heavy smokers could be targeted in a screening strategy.  In this way, 
the positive predictive value of the test being used would increase.  Additionally, meaningful cases (those 
that could cause significant morbidity and mortality) would be found, while low-grade disease would be 
left to be discovered by symptoms.  Unfortunately, there is a distinct lack of information in the bladder 
cancer literature linking different risk factors with specific subtypes of cancer.  Such information would 
be invaluable in the formation of an effective screening program, and is one of the greatest areas of need 
for future research. 
Potential Screening Tests 
 Bladder cancer is an attractive candidate for screening in that evidence of tumor growth can be 
found in the urine itself.  This offers the possibility of screening tests that are extremely simple to 
administer, assuming they have appropriate sensitivities and specificities for screening purposes.  One 
such test is urine dipstick testing for hematuria.  Painless gross hematuria is often one of the first visible 
symptoms of bladder cancer (5).  However, early asymptomatic bladder cancer can also be associated 
with microscopic bleeding (19).  Urine dispticks are a very quick and inexpensive way of searching for 
such occult bleeding.  False-positives may result from myoglobin in the urine, and false-negatives may be 
produced by high concentrations of ascorbic acid or from prolonged exposure of dipsticks to air.  
Microscopic hematuria in patients with asymptomatic bladder cancer is often intermittent; therefore, the 
ability to test multiple times at home is desirable.  Urine dipsticks allow for this possibility.   
One major drawback to testing for hematuria as a screening modality is the low specificity of 
hematuria for bladder cancer.  Results of a prospective study of 1,034 patients by Muramaki and 
colleagues showed that men with asymptomatic hematuria had a diverse array of causes of their bleeding, 
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and up to 55% of these men had no identifiable source of bleeding (20).  Other possible causes of 
asymptomatic hematuria include bladder stones, benign prostatic hypertrophy, renal cysts, exercise, 
asymptomatic infection, and many more.  For hematuria testing to be useful as a screening test, the target 
group would need to have a sufficiently high prevalence of bladder cancer such that the positive 
predictive value of the test is reasonable. 
 Urine cytology is another potential screening test for bladder cancer.  Urothelial cells involved in 
cancerous processes will undergo cytologic changes, and when these cells are shed into the urine they can 
be viewed and interpreted by a pathologist.  The use of cytology as an initial screening test is limited by 
several factors, including the need of a pathologist for interpretation and its relatively high cost.  Another 
possible screening test is office cystoscopy.  Using a flexible cystoscope, the urologist is able to achieve 
direct visualization of the urothelium, and it is the gold standard for the initial diagnosis and staging of 
bladder cancer.  The utilization of cystoscopy as a screening tool for a broad population, however, is 
extremely limited due to its invasive nature and high cost.  No trials have been performed to evaluate its 
effectiveness as a screening tool, even in a very high-risk population.   
More promising are newer, urine-based bladder tumor markers (UBBTMs), which detect tumor-
specific molecular markers that are shed into urine.  Like urine testing for hematuria, these offer the 
advantages of being quick, painless, and easy to administer.  Also similar to dipstick testing for 
hematuria, they will need to have acceptable sensitivities and specificities to be useful as screening tools.  
Some of these markers include nuclear matrix protein-22 (NMP-22), bladder tumor antigen (BTA), 
UroVysion FISH, and ImmunoCyt.  These markers have been studied extensively with regards to cancer 
surveillance (21).  However, their role in screening has yet to be defined. 
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Necessary Evidence for Recommendation of Screening 
The underlying premise behind any given successful screening program is that early detection will 
improve disease-specific morbidity and/or mortality.  Thus, it is necessary that studies involving 
asymptomatic screened and unscreened groups show an improvement in either morbidity or mortality for 
the screened group through long-term follow-up (preferably shown through a randomized controlled 
trial).  Inherent in this improved prognosis is the principle that treatment of the disease is more effective 
when the disease is detected before symptoms manifest (22).  Furthermore, a disease that is suitable for 
screening must be detectable during this preclinical phase by a relatively inexpensive test.  Any benefit 
that is derived from earlier detection of the disease must outweigh costs of screening, including financial 
cost, psychological burden of false positives, and health-related costs, to be detailed below (23).  To 
summarize, an effective screening program must detect the specific disease in a preclinical state, 
treatment of the disease must work better in this preclinical state than when the disease presents clinically, 
screened patients must experience improved disease-specific outcomes, and the benefits of screening 
must outweigh the costs. 
 Since the purpose of screening is to detect disease in its preclinical state, the disease needs to 
have a reasonably long preclinical phase for screening to be successful.  Longer preclinical phases lead to 
higher prevalence of people in this phase.  If this phase is short and patients rapidly progress to become 
symptomatic, then the purpose of screening is lost.  Integral to the necessity of having a relatively long 
preclinical phase is the importance of having a high predictive value, both positive and negative, for the 
screening test.  If the prevalence of people in the preclinical phase is high, then the positive predictive 
value will be higher.  However, a short preclinical phase will produce a lower prevalence of people in this 
state and a low positive predictive value.  Although the natural history of bladder cancer is not entirely 
clear, it appears that this disease may not have a long preclinical phase.  This is evidenced by the fact that 
bladder cancer is almost never found incidentally on autopsy (24).  Finally, any test used for screening 
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purpose must have a relatively high sensitivity and specificity.  This is particularly important in a disease 
like bladder cancer, which has a prevalence that is significantly lower than many other diseases that are 
currently detected with screening.  High sensitivity and specificity for the chosen test will limit false 
positives and false negatives, which can produce both psychological and bodily harm. 
Potential Harms of Screening 
The harms of any screening program can be broken down into different types of “costs”.  The first is 
literal financial cost.  A potential screening test must be relatively inexpensive; if it is extremely costly, it 
cannot be used in a widespread manner.  Furthermore, very expensive tests are not likely to outweigh 
their cost through improved disease prognosis.  Another possible harm involves false positive and false 
negative results.  False positives are harmful for a number of reasons.  These results give the patient a 
label and the mistaken prospect of dealing with a disease they do not have, creating significant anxiety.  
Further, positive results lead to further confirmatory testing, which is unnecessary and involve significant 
risk.  For example, initial testing for bladder cancer is followed up with cystoscopy, which is invasive in 
nature and not without certain risks.  False negatives are also harmful in that those with the disease are 
provided false reassurance about the absence of disease. 
 Even in the case that the result of a screening test is a true positive, there may still be overall 
harm from screening.  Apart from the true positive scenario wherein the patient‟s disease course will be 
improved based on the fact that it was detected preclinically, there are several other scenarios where 
screening would not be helpful.  The first is the patient who has rapidly progressive disease, and who 
would have died at the same time regardless of when they were diagnosed.  The second is the patient who 
has easily treated disease.  In this case, their disease would have been treated just as well if it had been 
discovered clinically.  The last scenario is the patient whose disease would have never manifested 
clinically during the patient‟s lifetime.  This is an example of overdiagnosis, and necessarily leads to 
labeling, further testing, and treatment which can only be classified as harmful.  Overdiagnosis with 
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regard to bladder cancer screening may or may not be a problem.  The fact that bladder cancer is almost 
never found incidentally on autopsy implies that all bladder cancer eventually becomes problematic, and 
thus overdiagnosis would not occur through screening.  However, since a majority of newly diagnosed 
bladder tumors are low-grade, and these tumors are unlikely to invade muscle, these cancers may be 
classified as overdiagnosed.  Unfortunately we do not know the natural history of such tumors, as no 
studies have compared treatment versus “watchful waiting” in these patients; these tumors are always 
immediately resected, and the patient is placed on a rigorous surveillance schedule (9).  Therefore, it is 
difficult to know whether overdiagnosis occurs.  In every true positive scenario, the patient is receiving a 
label earlier in the disease course than they would have if diagnosed clinically, entailing a psychological 
burden. 
Research Question/Study Design 
 To evaluate the potential benefits and harms of screening for bladder cancer, I will conduct a 
systematic review of the literature.  In the absence of our ability to conduct a large, prospective, 
randomized controlled trial, this may be the most informative way to move forward on the issue.  This 
systematic review will attempt to answer several key questions: 
1. Does screening for bladder cancer lead to decreased morbidity or mortality? 
2. Do potential screening modalities have appropriate test characteristics, including a high 
sensitivity and specificity, low cost, and an acceptable ease of administration to warrant their use 
as screening tests in asymptomatic, high-risk populations? 
3. Does earlier treatment reduce morbidity and mortality more than later treatment? 
4. What are the harms of screening? 
5. What are the potential harms of a full urologic workup? 
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Methods 
Key Question 1 
 Perhaps the most important question when considering the implementation of a widespread 
screening protocol is whether screening leads to decreased disease-specific morbidity or mortality.  If 
those screened experience the same burden of disease as those who are not screened, then the potential 
harms of screening, including anxiety, extensive and expensive diagnostic workups, and possible 
overtreatment will be the determining factors in whether or not to implement a screening program.  In this 
case, a lack of benefits will lead to a recommendation against screening.  However, if screening can be 
found to significantly improve morbidity and mortality, then these benefits may outweigh the potential 
harms.  I will not be reviewing articles studying sensitivity or specificity of certain tests or harms of 
testing and treatment here, which will be covered in separate key questions.  
Eligibility Criteria 
 Articles included to answer this focused question were limited to prospective, randomized, 
controlled trials published between 1982 and 2010.  1982 was chosen as the starting date since this was 
the year that information regarding the natural history of bladder cancer was first published (8).  Non-
English-language articles were excluded.  Only studies published in a peer-reviewed journal were 
included.  Studies were limited to those with at least 1,000 screened subjects in order to capture a 
population large enough to have a reasonable chance of finding prevalent disease.  Studies involving 
groups screened from high-risk urological clinics were excluded.  Similarly, only studies with 
asymptomatic screened groups were considered.  Follow-up periods were required to average at two years 
for studies to be included.  Extensive follow-up periods are necessary in order to appropriately measure 
differences in morbidity and mortality.  Although we believe that the population that may be most 
effectively targeted by a bladder cancer screening program is males over age 50, we did not limit our 
15 
 
analysis in terms of population demographics, nor were studies excluded on the basis of control group 
characteristics.  Studies were likewise not limited to a specific screening test or a specific testing interval.  
Only studies reporting the outcomes of disease-specific mortality rates and/or morbidity, including 
recurrences, disability-adjusted life-years (DALY‟s), and quality-adjusted life-years (QALY‟s) were 
included. 
 As database searching proceeded, the eligibility requirements were expanded to include any 
observational study, due to a lack of any studies meeting all of the eligibility criteria listed above.  
Additionally, studies lacking a control group were also admitted in order to allow one of the two studies 
widely cited as the best available evidence on bladder cancer screening currently available (41-44).  A full 
listing of inclusion criteria is presented in table 1 below: 
       Table 1: Inclusion Criteria (Key Question 1)___ 
Randomized trials or observational studies published 
between 1982 and 2010 
Published in a peer-reviewed journal 
English-language 
Full-text articles 
>1,000 subjects in screened group 
Subjects in screened group were asymptomatic 
Minimum 2 years mean follow-up 
Outcomes: disease-specific mortality and/or indices of 
morbidity 
Setting: primary care 
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Search Strategy 
Searches were performed through MEDLINE, EMBASE, and the Cochrane database of reviews and trials 
during April 2010.  We initially searched MEDLINE using the MeSH term “urinary bladder neoplasms”, 
which we combined with other MeSH terms “mass screening”, “early detection of cancer”, “morbidity” 
and “mortality”, as well as the text words “bladder cancer”, “carcinoma”, “transitional cell”, “screening”, 
“treatment outcome”, “mortality” and “morbidity”.  All MeSH terms are by default “exploded”.  The full 
search as entered into MEDLINE is shown below: 
("urinary bladder neoplasms"[MeSH Terms] OR bladder cancer[text word] OR bladder carcinoma[text 
word] OR “transitional cell carcinoma”[text word]) AND ("mass screening"[MeSH Terms] OR "early 
detection of cancer"[MeSH Terms] OR screening[text word]) AND (("mortality"[Subheading] OR 
"mortality"[All Fields] OR "mortality"[MeSH Terms]) OR ("epidemiology"[Subheading] OR 
"epidemiology"[All Fields] OR "morbidity"[All Fields] OR "morbidity"[MeSH Terms] OR “treatment 
outcome” [MeSH Terms])) 
This search was then repeated for EMBASE and the Cochrane library.  Reference lists of relevant review 
articles were then searched for further potential sources.  Finally, personal collections of articles from 
practicing urologists were searched for any remaining studies that fit our eligibility criteria. 
Quality Criteria 
We critically appraised and quality-rated individual studies that met eligibility criteria by using quality 
criteria adapted from the methods described by the United States Preventive Services Task Force (26).  
The USPSTF has delineated quality criteria that are specific to study design, dividing studies into five 
general categories: systematic reviews, case-control studies, randomized controlled trials, cohort studies, 
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and diagnostic accuracy studies.  These criteria focus on grading the internal validity, or the degree to 
which causal inferences can be made based on the design of the study.  The specific criteria used for case-
control studies, randomized controlled trials and cohort studies are presented in appendix 1 below.  A 
rating of “good”, “fair”, or “poor” was assigned for each study for its internal validity.  A “good” study 
met all or nearly all of the criteria for that particular research design, a “fair” study did not meet all 
criteria but did not have a flaw that invalidated its findings, and a “poor” study did have a flaw that 
invalidated its findings.   
External validity, or the generalizability of results to other populations, was also considered in the overall 
quality rating.  Again, a rating of “good”, “fair,” or “poor” was assigned for each study for its external 
validity.  The main variables that factored into this judgment included the degree of similarity between 
the population studied and the potential screening population, similarity in setting between the study 
population and a screening population, and the degree of similarity between the test being studied and the 
test that would be available for use in a widespread screening program.  Additionally, the research design 
used (i.e. case-control or RCT) was also factored into the overall quality rating, according to the 
USPSTF-defined hierarchy of research design (26).  This hierarchy is as follows: 
I: Properly conducted randomized controlled trial (RCT) 
II-1: Well-designed controlled trial without randomization 
II-2: Well-designed cohort or case-control analytic study 
II-3: Multiple time series with or without the intervention; dramatic results from uncontrolled experiments 
III: Opinions of respected authorities, based on clinical experience; descriptive studies or case reports; 
reports of expert committees 
Thus, for each study an overall quality rating of “good”, “fair” or “poor” was given.  The main variables 
that were used for this rating were internal validity, external validity, and research design.  Well-designed 
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studies that may rank lower on the hierarchy of research design with a high degree of internal and external 
validity may in fact provide more accurate information than poorly-designed studies that are higher on the 
hierarchy.  Likewise, a study‟s research design may be so weak as to be less informative than an RCT 
with several flaws.   
Finding and selecting articles 
The author and a second reviewer performed the main database searches.  Both reviewers examined titles 
and abstracts of the results of the search.  Articles that clearly did not address the key question were 
excluded.  Full-text review of the remaining articles was then performed by both reviewers, and studies 
that did not meet eligibility criteria were excluded.  The final set of studies was then dually examined, and 
study information was exported to three separate evidence tables by the author.  These tables are 
presented in appendix 2.  The first table was designed to capture general descriptive characteristics of 
each study. The second table captured criteria used for determination of internal and external validity, and 
the third table was designed to present overall results of the studies.  The data abstracted into the tables 
was then verified by the second reviewer, and disagreements about data abstraction or quality appraisal 
was resolved by consensus.  Evidence from these abstraction forms was then synthesized in a qualitative 
manner given the lack of comparability in study designs between the included studies.  Any discrepancies 
in interpretation were resolved between the two reviewers, and further disagreements were adjudicated by 
a third party.    
Key Question 2 
 Another necessary question to consider when evaluating potential screening programs is whether 
there are existing screening tests that have appropriate characteristics for screening purposes.  
Specifically, these tests need to have a reasonably high sensitivity and specificity, they need to be 
relatively inexpensive, and they need to have an acceptable ease of administration.  Bladder cancer is 
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unique in that evidence of the cancer can be detected in urine, making bladder cancer an attractive 
candidate for a screening program.  I will be reviewing the sensitivity, ease of administration, and cost 
characteristics of urinalysis testing for hematuria and urine cytology.  Additionally, I will be reviewing 
the following FDA-approved urine-based bladder tumor markers: nuclear matrix protein 22 (NMP22), 
bladder tumor-associated antigen stat-test (BTA-stat), UroVysion FISH, and ImmunoCyt.  The potential 
harms of each test reviewed will not be examined here, but rather in key question 4. 
 
Eligibility Criteria 
Articles included to answer this focused question were limited to randomized trials, observational studies 
and systematic reviews and/or meta-analyses published between 1982 and 2010.  1982 was chosen as the 
starting date since this was the year that information regarding the natural history of bladder cancer was 
first published (8).  Non-English-language articles were excluded.  Articles were included in our study if 
they included one of the six possible screening modalities listed above.  Studies were only included if 
they used invasive cystoscopy and/or histopathology as the reference standard.  We excluded studies that 
did not report enough information to produce a 2x2 contingency table.  Finally, the modality being tested 
was required to make a diagnosis of primary bladder cancer, as opposed to recurrent cancer.  In this way, 
the studies included would be testing for the same type of bladder cancer as a screening program.  We 
required studies to report both sensitivity and specificity in order to be included.  We did not limit our 
analysis in terms of population demographics, nor were studies excluded on the basis of control group 
characteristics.  Our analysis was similarly not limited on the basis of research design (cohort or case-
control).  Inclusion criteria is summarized in table 2 below: 
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Table 2: Inclusion criteria (Key Question 2) 
Randomized trials, observational studies and systematic reviews/meta-
analyses published between 1982 and 2010 
Published in a peer-reviewed journal 
Full-text articles 
English-language 
Tested diagnostic accuracy of hematuria, urine cytology, NMP22, 
UroVysion, BTA-stat or ImmunoCyt 
Used cystoscopy and/or histopathology as reference standard 
Information provided for construction of 2x2 contingency table 
Diagnosis of primary bladder cancer made 
 
Search Strategy 
Searches were performed through MEDLINE, EMBASE, and the Cochrane database of reviews and trials 
during April 2010.  We initially searched MEDLINE for studies of diagnostic accuracy that looked at 
hematuria by using the MeSH terms “Urinalysis” and “hematuria” combined with the MeSH terms 
“sensitivity and specificity” and “urinary bladder neoplasms”, as well as the text words “bladder cancer”, 
“carcinoma”, and “transitional cell”.  All MeSH terms are by default “exploded”.  The full initial search 
as entered into MEDLINE is shown below: 
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(“Urinalysis”[MeSH] OR “hematuria”[MeSH]) AND ("urinary bladder neoplasms"[MeSH Terms] OR 
bladder cancer[text word] OR bladder carcinoma[text word] OR “transitional cell carcinoma”[text word]) 
AND (“sensitivity and specificity”[MeSH Terms]) 
This search was then repeated in an altered form by replacing the term “sensitivity and specificity” with 
the MeSH term “costs and cost analysis”.  These two searches were then performed to search for studies 
of diagnostic accuracy looking at urine cytology by replacing the terms “urinalysis” and “hematuria” with 
the MeSH term “cytological techniques” and the text word “urine cytology” as shown below: 
(“Cytological techniques”[MeSH] OR “urine cytology”[text word]) AND ("urinary bladder 
neoplasms"[MeSH Terms] OR bladder cancer[text word] OR bladder carcinoma[text word] OR 
“transitional cell carcinoma”[text word]) AND (“sensitivity and specificity”[MeSH Terms])  
Next, searches were performed that focused on the four urine based bladder tumor markers, NMP22, 
BTA-stat, UroVysion and ImmunoCyt.  To search for studies of diagnostic accuracy concerning NMP22, 
the text words “NMP22” and “nuclear matrix protein 22” were combined with the MeSH terms 
“sensitivity and specificity”, “tumor markers, biological”, and “antigens, neoplasm” as shown below: 
 (“NMP22”[text word] OR “nuclear matrix protein 22”[text word]) AND (“sensitivity and 
specificity”[MeSH Terms]) AND (“tumor markers, biological”[MeSH Terms] OR 
“antigens,neoplasm”[MeSH Terms]) 
This search was then repeated by replacing “sensitivity and specificity” with the MeSH term “costs and 
cost analysis”.  These two searches were then repeated for the other three urine based tumor markers, 
using the text words “ImmunoCyt”, “bladder tumor-associated antigen”, “BTA-stat”, “UroVysion”, 
“UroVysion FISH”, and the MeSH term “In Situ Hybridization, Fluorescence”.  All searches were then 
repeated for EMBASE and the Cochrane library.  Reference lists of relevant review articles were searched 
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for further potential sources.  Finally, personal collections of articles from practicing urologists were 
searched for any remaining studies that fit our eligibility criteria. 
Quality Criteria 
The criteria used for assessing the methodological quality of each study were again adapted from 
USPSTF guidelines (26).  These criteria for internal validity are listed in appendix 3.  Studies of 
diagnostic accuracy are susceptible to several unique types of bias and variation (27).  These biases can be 
attributed to five general sources, including the population used, the test protocol performed, the reference 
standard and verification procedure used, interpretation of the test, and analysis of results.  The study 
population selected can have an effect both on the generalizability of the study as well as the performance 
of the test itself.  Tests may perform differently in various samples; therefore, it is important that a wide 
spectrum of subjects is included.  Choice of controls is similarly important.  For example, healthy controls 
are expected to yield fewer false positive results than patients with other urological disorders, affecting 
specificity (27).  Furthermore, if the study population is not similar to the population in which the test will 
be used in practice, in this case a primary care population, then the external validity of the study is 
weakened. 
 Differences in test protocol are also sources of variation between studies of diagnostic accuracy.  
In each study, it is important that the authors provide a sufficient description of the execution of both the 
index test and reference standard.  Additionally, the reference standard should be applied in a reasonable 
amount of time following the index test.  Disease progression bias can occur if the index test is performed 
an unusually long time before the reference standard, at a time when the disease is likely to be at a more 
advanced stage (27).  Although it may seem obvious, the reference standard should be the “gold standard” 
for diagnosis of the disease; errors of an imperfect reference standard can bias the measurement of 
diagnostic accuracy of the reference test.  The reference standard should be applied to all subjects, 
regardless of their index test results in order to avoid verification bias.  Verification bias occurs when the 
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decision to perform the reference test is based on the results of the index test (27).  This bias is partial 
when only a sample of negative index tests are subjected to the reference standard, and differential when 
patients with a certain index test result receive a different reference standard.  In studies of diagnostic 
accuracy, it is also important that all patients presenting with the relevant condition are included in order 
of entry in order to avoid selection bias (52).  Another method is to include a random subset of these 
patients.  Inclusion of subjects that are non-random and non-consecutive is a clear source of selection 
bias. 
 Interpretation and analysis of index test results also can have a large impact on the internal 
validity of a study of diagnostic accuracy.  The reference standard and index test should be interpreted 
independently of the results of the other test in order to avoid review bias.  Review bias occurs when 
interpretation of one test is influenced by knowledge of the results of the other test, often leading to 
overestimation of diagnostic accuracy of the test being studied.  For this reason, it is important that 
interpretation of each test is blinded to the results of the other test.  Analysis of indeterminate results can 
also play a large role in the study of diagnostic accuracy.  Often these results are not reported, but rather 
simply removed from the analysis (27).  This can lead to biased assessment of the test characteristics.  
Selection of the threshold value for the index test should be specified by the authors.  Finally, it is 
important to note industry sponsorship of studies, as this has been shown to affect diagnostic accuracy 
(29).  All of the aforementioned potential sources of bias and variation were examined and incorporated 
into our assessment of internal validity for each study. 
 Similar to key question 1, we qualitatively assessed the internal validity, external validity, and 
overall quality of each study.  For each of these three assessments, we again assigned a grade of “good”, 
“fair”, or “poor”.  Research design was also taken into consideration.  For studies of diagnostic accuracy, 
cohort designs are considered to be more conservative, as case control designs have been shown to lead to 
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overestimations of sensitivity and specificity (28).  This generally occurs because in a case control study, 
a relatively sick population is compared to a relatively healthy population. 
 A separate set of criteria was used to evaluate the quality of systematic reviews and/or meta-
analyses.  Several characteristics have been deemed extremely important in the formation of a well-
conducted systematic review, as defined by the PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses) statement (51).  First, the review must be based on a focused key question.  
A comprehensive literature search strategy should be used and reported.  The authors should use a 
standard method to appraise the internal validity of included studies.  Publication bias should be assessed, 
wherein studies that have “significant” results are more likely to be published than those that do not.  
Finally, the authors must address statistical heterogeneity, and the statistical analysis must be adequate.  
An overall quality rating of “good”, “fair”, or “poor” was assigned to each systematic review or meta-
analyses included. 
Finding and selecting articles 
The author and a second reviewer performed the main database searches.  Both reviewers examined titles 
and abstracts of the results of the search.  Articles that clearly did not address the key question were 
excluded.  Full-text review of the remaining articles was then performed by both reviewers, and studies 
that did not meet eligibility criteria were excluded.  The final set of studies was then dually examined, and 
study information was exported to four separate evidence tables by the author.  These tables are presented 
in appendix 4.  The first table was designed to capture general descriptive characteristics of each study. 
The second table captured criteria used for determination of internal and external validity, and the third 
table was designed to present overall results of the studies.  The fourth table represents the abstraction 
form for systematic reviews and/or meta-analyses.  The data abstracted into the tables was then verified 
by the second reviewer, and disagreements about data abstraction or quality appraisal was resolved by 
consensus.  
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Key Question 3 
For a widespread screening program for bladder cancer to be successful, it is necessary for earlier 
treatment of the disease to have morbidity and/or mortality benefits over later treatment.  The purpose of 
screening is to find disease at an earlier, hopefully more treatable stage.  In the case of bladder cancer, 
screening would be effective if those tumors that are bound to become muscle-invasive are discovered 
before they have invaded muscle.  If these cancers are subsequently treated, it would be reasonable to 
expect a mortality benefit for these patients than if they had presented clinically with muscle-invasive 
disease.  However, identifying which tumors are most likely to invade muscle may prove to be difficult.  
Furthermore, for other bladder cancers which may not invade but have a high chance of recurrence, 
earlier treatment may have no benefit at all over later treatment.  The highest level of evidence to answer 
this question would be a randomized controlled trial.  In such an RCT, patients diagnosed with bladder 
cancer would be divided into two groups: one which is treated immediately, be it with surgery, 
radiotherapy, or chemotherapy, and the other which is treated at a later time.  In the unlikely event that 
such a trial has been performed, cohort or case-control studies would also provide some evidence as to the 
benefit of treating bladder cancer earlier in its disease course as opposed to later.  Evidence for answering 
this key question need not come specifically from a study on screening. 
Eligibility Criteria 
Articles included to answer this focused question were limited to randomized trials and observational 
studies published between 1982 and 2010.  Non-English language articles were excluded.  We were most 
interested in treatment of primary bladder cancer as opposed to recurrences, as any prevalent cancer 
identified through screening would necessarily be a primary cancer.  Therefore, we excluded studies that 
also looked at treatment decisions after finding recurrent cancers.  Follow-up was to be at least two years 
after time of diagnosis.  Only studies reporting the outcomes of disease-specific mortality rates and/or 
morbidity, including recurrences, disability-adjusted life-years (DALY‟s), and quality-adjusted life-years 
26 
 
(QALY‟s) were included.  We did not limit our analysis in terms of population demographics, nor were 
studies excluded on the basis of control group characteristics.  Full inclusion criteria are listed in table 3 
below: 
Table 3: Inclusion Criteria (Key Question 3) 
Randomized trials and observational studies published 
between 1982 and 2010 
Published in a peer-reviewed journal 
Full-text articles 
English-language 
Diagnosis of primary bladder cancer made with 
subsequent treatment decision and follow-up 
Comparison between two groups made: immediate 
treatment vs. expectant management among those with 
early-stage tumors 
At least 2 years of average follow-up 
Outcomes: disease-specific mortality and/or indices of 
morbidity 
Setting: primary care 
 
Search Strategy 
Searches were performed through MEDLINE, EMBASE, and the Cochrane database of reviews and trials 
during April 2010.  We initially searched for the MeSH term “urinary bladder neoplasms”, which we 
combined with the MeSH terms “mortality” and “treatment outcomes”, as well as the text words “delay”, 
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“prognosis”, “survival”, and “transitional cell carcinoma” and “bladder carcinoma”.  The full search as 
entered into MEDLINE is shown below: 
("urinary bladder neoplasms"[MeSH Terms] OR “bladder cancer”[text word] OR “bladder 
carcinoma”[text word] OR “transitional cell carcinoma”[text word]) AND (“early detection of cancer” 
[MeSH terms]) AND ("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH Terms] 
OR "morbidity"[All Fields] OR "morbidity"[MeSH Terms] OR “treatment outcome”[MeSH terms] OR 
“survival”[text word]) AND “delay”[text word]) 
This search was then repeated for EMBASE and the Cochrane library.  Reference lists of relevant review 
articles were then searched for further potential sources.  Finally, personal collections of articles from 
practicing urologists were searched for any remaining studies that fit our eligibility criteria. 
Quality Criteria 
We again used quality criteria adapted from the methods described by the USPSTF (26) to critically 
appraise and rate the quality of individual studies.  The criteria for randomized controlled trials, cohort 
studies and case-control studies are listed in appendix 1.  These criteria were used for the determination 
of each study‟s internal validity, which again was given a score of “good”, “fair” or “poor”.  Likewise, we 
also gave a score of “good”, “fair” or “poor” to each study for its external validity, as well as for the 
overall study quality.  Research design was again factored into our appraisal of overall study quality and 
persuasiveness of findings. 
Finding and selecting articles 
The approach for finding and selecting articles, as well as data abstraction and evaluation was the same 
for this key question as that described for key questions 1 and 2 listed above.  Specific evidence tables 
designed for answering key question 3 are listed in appendix 5 below. 
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Key Question 4 
Every widespread screening program entails some risk of harm to those who are screened.  As outlined in 
potential harms of screening above, screening programs are effective when disease is found at an 
earlier, more treatable stage, and treating at this stage results in better outcomes than treating at a later 
stage.  However, there is still a chance that many patients who are screened can experience harm, both 
psychological and physiological.  Patients who receive a false positive result on their screening test are 
then subjected to further invasive tests.  In the case of bladder cancer, the next step is a full urologic 
workup including cystoscopy, which is certainly invasive and subjects the patient to a certain degree of 
physiological risk.  Patients are also subjected to comprehensive imaging, increasing their radiologic 
exposure greatly.  Screening also entails some psychological risk, as those who receive a positive result 
(either true or false) are given a label, in addition to potentially significant psychological anxiety.  For this 
key question, I will be reviewing the literature for potential harms of screening.  I will focus on the effects 
of increased testing and psychological burden on those who are screened, and therefore the literature 
search will necessarily focus on those studies that have implemented screening trials.  I will include the 
amount of unnecessary testing and treatment among patients with false positive results as evidence 
towards answering this question; however, detailing the actual harms of treatment will be left to key 
question 5. 
Eligibility Criteria 
Our eligibility criteria for key question 4 were the same as those outlined for key question 1 out of 
necessity.  Since key question 1 identified those studies that had actually implemented a trial of screening 
for bladder cancer, this key question identified the only studies that have the ability to detail the harms of 
screening.  The full inclusion criteria are listed in table 4 below.  We included only studies that had a 
minimum of 2 years of follow up from initial screening.  Many of the potential harms could take months 
and even a number of years to develop, especially in true positive cases that may be representative of 
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overdiagnosis.  Our key outcomes for this question were different than those listed for key question 1; 
here, we were interested in the psychological effects of screening, as well as estimates of the amount and 
invasiveness of unnecessary testing and treatment.  We did not exclude studies on the basis of research 
design, nor on the basis of patient demographics.  Due to the small number of available studies that have 
focused on screening trials for bladder cancer, we likewise did not exclude studies on the basis of what 
instruments the authors may have used to assess harms of screening. 
       Table 4: Inclusion Criteria (Key Question 4)___ 
Observational studies published between 1982 and 2010 
Published in a peer-reviewed journal 
English-language 
Full-text articles 
>1,000 subjects in screened group 
Subjects in screened group were asymptomatic 
At least 2 years of average follow-up 
Outcomes: psychological harm, unnecessary testing and 
treatment 
Setting: primary care 
 
Search Strategy 
Searches were performed through MEDLINE, EMBASE, and the Cochrane database of reviews and trials 
during April 2010.  We initially searched MEDLINE using the MeSH term “urinary bladder neoplasms”, 
which we combined with other MeSH terms “mass screening”, “early detection of cancer”, “Stress, 
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psychological”, “Psychiatric status rating scales”, “health status”, “severity of illness index”, “quality of 
life”, “false positive reactions” and “false negative reactions”, as well as the text words “bladder cancer”, 
“bladder carcinoma”, “transitional cell carcinoma”, and “screening”, in addition to the subheadings 
“adverse effects”, “complications”, and “statistics and numerical data”.  The full search as entered into 
MEDLINE is shown below: 
("urinary bladder neoplasms"[MeSH Terms] OR bladder cancer[text word] OR bladder carcinoma[text 
word] OR “transitional cell carcinoma”[text word]) AND ("mass screening"[MeSH Terms] OR "early 
detection of cancer"[MeSH Terms] OR screening[text word]) AND (“Stress, psychological”[MeSH 
Terms] OR “Psychiatric Status Rating Scales”[MeSH Terms] OR “Health Status”[MeSH Terms] OR 
“Severity of Illness Index”[MeSH Terms] OR “Quality of Life”[MeSH Terms] OR “False Positive 
Reactions”[MeSH Terms] OR “False Negative Reactions”[MeSH Terms] OR "adverse 
effects"[Subheading] OR "complications"[Subheading] OR “statistics and numerical data”[Subheading]) 
This search was then repeated for EMBASE and the Cochrane library.  Reference lists of relevant review 
articles were then searched for further potential sources.  Finally, personal collections of articles from 
practicing urologists were searched for any remaining studies that fit our eligibility criteria. 
Quality Criteria 
We again used quality criteria adapted from the methods described by the USPSTF (26) to critically 
appraise and rate the quality of individual studies.  The criteria for randomized controlled trials, cohort 
studies and case-control studies are listed in appendix 1.  These criteria were used for the determination 
of each study‟s internal validity, which again was given a score of “good”, “fair” or “poor”.  Likewise, we 
also gave a score of “good”, “fair” or “poor” to each study for its external validity, as well as for the 
overall study quality.  Research design was again factored into our appraisal of overall study quality and 
persuasiveness of findings. 
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Finding and selecting articles 
The approach for finding and selecting articles, as well as data abstraction and evaluation was the same 
for this key question as that described for key questions 1 and 2 listed above.  Specific evidence tables 
designed for answering key question 4 are listed in appendix 6 below. 
 
Key Question 5 
When a screening test for bladder cancer is positive, a full urologic workup is necessary.  Such a workup 
includes cystoscopy, urine cytology, and a radiographic evaluation of the upper urinary tract, which 
currently consists of  CT or MR urography, or renal ultrasound for those who have contraindications to 
contrast material (64).  This extensive workup is not without risks.  The principal risks with cystoscopy 
are the same as with any invasive procedure, namely bleeding and infection (28).  Radiographic imaging 
entails varying amounts of radiologic exposure depending on the method used.  When evaluating a 
potential screening program, it is important to know the potential harms that could result to patients who 
receive a positive result on the screening test.  In this way, we are able to evaluate whether the potential 
benefits of screening (delineated by the answers to key questions 1 and 3) outweigh the harms and risks of 
screening (detailed in key questions 4 and 5).   
Eligibility Criteria 
Articles included to answer this focused question were limited to observational studies and systematic 
reviews published between 1982 and 2010.  Non-English language articles were excluded.  We were most 
interested in the specific harms incurred by the various components of the urologic workup; therefore, we 
required each study included to specifically address harms.  We did not limit our search on the basis of 
research design, as many sources of diagnostic test harm information come from case series and other 
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types of publication.  We also did not limit our search on the basis of patient demographics; many case 
series are expected to be published from a high-risk, urologic population.  
Search Strategy 
Searches were performed through MEDLINE, EMBASE, and the Cochrane database of reviews and trials 
during April 2010.  We initially searched MEDLINE using the MeSH term “Cystoscopy”, combined with 
the subheadings “adverse effects”, “complications”, “mortality”, and “statistics and numerical data”, as 
well as the MeSH term “mortality” and the text word “cystourethroscopy”.  The full search as entered into 
MEDLINE is shown below: 
(“Cystoscopy”[MeSH Terms] OR “Cystourethroscopy”[text word]) AND (“mortality”[MeSH terms] OR 
“mortality”[Subheading] OR “adverse effects”[Subheading] OR “complications”[Subheading] OR 
“statistics and numerical data”[Subheading]) 
The search was then repeated three separate times for the three imaging modalities (CT urogram, MR 
urogram, and renal ultrasound).  For CT urogram, the MeSH terms “Tomography, X-Ray Computed” and 
“urography” were combined with the text words “abdomen”, “pelvis”, “abdominal CT”, “pelvic CT”, 
“urogram” and “CT”, along with the other terms of the search.  For MR urogram, the MeSH term 
“Magnetic Resonance Imaging” and “urography” were combined with the text words “MRI”, “MR”, and 
“urogram”, along with the other terms of the search.  For renal ultrasound, the MeSH term 
“ultrasonography” was combined with the text word “renal ultrasound” and the other terms of the search.   
All searches were then repeated for EMBASE and the Cochrane library.  Reference lists of relevant 
review articles were then searched for further potential sources.  Finally, personal collections of articles 
from practicing urologists were searched for any remaining studies that fit our eligibility criteria. 
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Quality Criteria 
We again used quality criteria adapted from the methods described by the USPSTF (26) to critically 
appraise and rate the quality of individual studies.  The criteria for randomized controlled trials, cohort 
studies and case-control studies are listed in appendix 1.  These criteria were used for the determination 
of each study‟s internal validity, which again was given a score of “good”, “fair” or “poor”.  Likewise, we 
also gave a score of “good”, “fair” or “poor” to each study for its external validity, as well as for the 
overall study quality.  Research design was again factored into our appraisal of overall study quality and 
persuasiveness of findings. 
Finding and selecting articles 
The approach for finding and selecting articles, as well as data abstraction and evaluation was the same 
for this key question as that described for key questions 1 and 2 listed above.  Specific evidence tables 
designed for answering key question 5 are listed in appendix 6 below. 
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Results 
 
Key Question 1 
Search Results 
Performance of our search through MEDLINE, EMBASE, and the Cochrane database, in addition to 
review of reference lists yielded an initial total of 222 articles.  Of these, we excluded 142 citations.  The 
majority of these exclusions were done on the basis of title review, as they were clearly not related to our 
study question.  125 of the 222 initial citations were excluded in this manner, leaving 97 citations for 
abstract review.  Of the 97 abstracts up for review, 16 were excluded because they were only published in 
abstract form.  Another two abstracts were excluded because we were unable to retrieve the full text; 
however, these articles would also have been excluded in the abstract review on the basis of failing to 
answer our key question (33,34).  On abstract review, a further 17 articles were excluded as the studies 
clearly did not meet eligibility criteria.  This left 62 articles for full-text review.   
Of the 62 articles reviewed in full-text form, 46 were review articles on the subject of screening 
for bladder cancer, and were thus excluded.  The remaining 16 articles all reported data from actual 
screening trials.  Six of these screening trials were excluded for the following reasons: three did not report 
mortality or indices of morbidity as an outcome (35-37), two did not use primary care patients as the 
study population in addition to a lack of mortality/morbidity reporting (38, 39), and one lacked the correct 
study population and had too few subjects (40).  After all exclusions, 10 articles remained (41-50), 
representing longitudinal data from two distinct screening studies that met our eligibility criteria.  All ten 
articles were included because they each contained unique information on the methodology and results of 
these studies that was not reported in the other articles.  These two studies will be described in detail 
below.  See figure 1 for a flow chart of included and excluded articles. 
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Figure 1: Flow chart of included and excluded studies, Key Question 1 
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Description of included studies 
Two studies of bladder cancer screening met our eligibility criteria and have presented longitudinal data 
on mortality.  The first, conducted by Britton and colleagues in Leeds, England (41-44), was a 
nonrandomized, non-controlled, prospective trial in which 3,152 men age 60 and older from five general 
practices were invited to participate in a bladder cancer screening trial from 1987 to 1989.  Of these, 
2,356 men (74.7%) accepted and entered into the trial.  Participants‟ urine was tested for hemoglobin by 
dipstick at an initial clinic, and thereafter subjects tested their own urine at home either once a week for 
ten weeks (1,604 men) or once a day for ten days (752 men).  The authors do not report how participants 
were divided into these two groups, and results are not reported for individual groups, only as a whole.  If 
any one of the eleven total urinary dipsticks was positive for hemoglobin, the participants were offered a 
full urologic workup, consisting of urine microscopy and culture, urine cytology, excretory urography 
and/or renal ultrasound, and cystoscopy and biopsy.   
 Of the 2,356 men who underwent screening, 474 (20%) had at least one positive test result for 
hematuria.  Of these, only 319 agreed to further urologic workup.  Upon pathologist review, 17 bladder 
cancers were detected.  This represents 0.7% of the entire screened cohort.  Additionally, the positive 
predictive value (PPV) is reported by the authors as 5.3% (17/319).  However, a more conservative 
estimate is 3.6% if using the total number of participants who received a positive result (474).  The true 
PPV for this cohort is likely somewhere between the two estimates. 
 Of the 17 bladder cancers detected through screening, only one (5.9%) was initially muscle-
invasive.  This figure is much lower than the 30% of disease that is typically muscle-invasive when 
diagnosed clinically (8).  These 17 patients were followed as a cohort for the next seven years and 
monitored for recurrences and progression of disease.  At seven years, 5 of the 17 cases (29%) had 
progressed to muscle invasion.  Further, there were recurrences among four other patients (23%).  At the 
end of the seven year follow-up period, three of these subjects had died of bladder cancer, making bladder 
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cancer-specific mortality 17.6%.  Three patients had died of other causes, for an all-cause mortality of 
35.2%.  The authors do not report any outcome data for study participants that did not have bladder 
cancer diagnosed, including those with a positive screen but negative urologic workup. 
 These results show that prevalent cases of bladder cancer can be detected through a screening 
program looking for hematuria, as we would expect.  Furthermore, it is possible that screening detected 
tumors that were destined to become muscle-invasive, as only one of the 17 detected cancers was 
invasive.  However, the study has a number of large weaknesses that make drawing conclusions from it 
extremely difficult, if not impossible.  Perhaps its greatest weakness is the study‟s lack of a control group.  
An ideal comparison group would have been a cohort of men over age 60 in the same geographical area 
that were not screened for bladder cancer.  Without this comparison, we cannot draw any conclusions as 
to whether screening was effective in reducing bladder cancer-related mortality.  Additionally, we do not 
know the outcome of the participants who did not have bladder cancer diagnosed.  We have no 
information on the rate of false negatives among these patients.   
 Another significant weakness with this study is its small size.  While only 2,356 men were 
screened, most screening trials have on the order of 70,000 to over 100,000 participants in order to catch a 
large enough number of prevalent cases to make meaningful evaluations.  The number of cancers detected 
in this study (17) is too small to evaluate the efficacy of screening, even if a control group were present.  
This is one factor tempering any conclusions drawn from the fact that only one of 17 cases was initially 
muscle-invasive.  This could be a down-staging due to screening; however, it could have been simply due 
to the role of chance in the small number of tumors detected.  Furthermore, it could also have been due to 
the presence of length-time bias, wherein down-staging appears to have occurred but in reality more 
indolent tumors are detected.   
 The study has several other inherent weaknesses.  All participants were volunteers, creating 
potential for selection bias as those who responded to invitation (and agreed to workup if they tested 
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positive) may have differed substantially from those declined.  Additionally, there is no data on drop-outs 
for follow-up rate over the initial testing period, and there is also limited information about exclusion 
criteria.  As a function of the number of large weaknesses, the internal validity of this study is poor.  
External validity is fair, as our population of interest includes older men in primary clinics, and the rate of 
bladder cancer in Leeds is not expected to differ significantly from that in the United States; however, this 
group consisted entirely of volunteers. The results of this study show that the subjects with bladder cancer 
detected by screening still did not fare incredibly well, as a significant number of them had progression of 
their disease and eventually succumbed to it.  Finally, the positive predictive value of hematuria for this 
cohort was very low (5.3% or 3.6%).  Although this may seem discouraging, it is difficult to draw any 
conclusions from this study; we rated its overall quality as “poor”. 
 The second study included for analysis, conducted by Messing and colleagues (45-50), was a 
nonrandomized controlled trial of screening by urinary dipstick.  From 1989 to 1992, men age 50 and 
older were invited to participate by way of a solicitation letter and informational brochure from four 
general practices in Madison, Wisconsin.  Of the 3,515 men invited, 1,575 (44.8%) agreed to participate.  
Subjects tested their urine at home by dipstick daily for 14 days, then repeated this procedure nine months 
later if all 14 of the original tests were negative for hemoglobin.  If a single test out of the 28 total was 
positive, the participant underwent a full urologic workup, consisting of a history and physical 
examination, blood tests (serum Creatinine, CBC and PT), microscopic urinalysis, urine culture, IV 
urography, cystoscopy and urine cytology.  The comparison group in this study consisted of all men over 
age 50 with bladder cancer reported to the Wisconsin cancer reporting system (WCRS) during the year 
1988.  The choice of this comparison group resulted in 509 controls. 
 Of the 1,575 screened participants, 258 (16.4%) tested positive for hematuria at least once.  Upon 
urologic workup, 21 cases of bladder cancer were found among these 258 men, for a positive predictive 
value of 8.1% (21/258).  The 21 detected cases represent 1.3% of the entire cohort.  For reporting grade 
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and stage, the authors divided patients into three categories: low grade, non-muscle invading (LGN), 
consisting of grades 1 and 2 and stages Ta and T1; high grade, non-muscle invading (HGN), consisting of 
grade 3 and stages Ta, T1 or Tis; and muscle-invasive (INV).  Of the 21 detected tumors, 11 (52.4%) 
were LGN, 9 (43%) were HGN, and one (4.8%) was invasive.  In the control group of cancers detected 
clinically and reported to WCRS, 309 (60%) were LGN, 80 (16%) were HGN, and 120 (24%) were 
invasive.  Therefore, a greater proportion of cancers detected clinically were already invasive as 
compared to those detected by screening. 
 After 14 years minimum follow-up, the authors report mortality data for the cohort of participants 
with bladder cancer detected by screening, as well as for the control group.  Outcomes for the entire 
screened group of 1,575 men are not reported.  After 14 years, none of the 21 patients with screening-
detected cancer had died of bladder cancer, whereas 104 of the 509 control patients had died of bladder 
cancer, a difference the authors report as significant (p = .02).  For overall mortality, nine of the 21 
patients with screening-detected cancer had died, whereas 273 of the 509 control patients had died, also a 
significant difference (p < .004).  Data on bladder cancer-specific morbidity, harms of workup and harms 
of treatment are not reported. 
 On first glance, these results would seem to suggest that earlier diagnosis of bladder cancer 
through hematuria screening resulted in a stage shift and ultimate mortality benefit.  However, similar to 
the study by Britton, this study has several major weaknesses that make it nearly impossible to draw any 
firm conclusions.  The study does have a control group, but the choice of a cancer registry as the 
comparison makes the study‟s results susceptible to certain biases.  While it appears that the group with 
bladder cancer detected by screening had better disease-specific and overall survival, this could be due 
entirely to lead-time bias.  In this scenario, cancer is detected earlier in its disease course, and the patient 
has a diagnosis for a longer period of time; therefore, it appears that the patient lives longer with the 
disease.  In reality, though, it is possible that those who were diagnosed clinically lived the same amount 
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of time with disease as those who were diagnosed by screening, but simply were diagnosed later in the 
disease course.  Time from diagnosis to death is shorter, but time from disease onset to death may not 
have been shorter.  On the other hand, it is also possible that screening did indeed have a mortality 
benefit, detecting cancers that were destined to become invasive before they did so.  However, with the 
use of a contemporaneous cancer registry as the control group, it is impossible for use to know whether 
the apparent benefit was real, due entirely to lead-time bias, or somewhere in-between.  Use of an 
appropriate comparison group by way of a randomized, controlled trial is the only way to definitively 
answer this question. 
 Aside from this major flaw, the study also has several other important weaknesses.  Outcomes for 
the 1,575 patients who were screened were not followed as a whole, only the 21 patients who had bladder 
cancer detected.  It is vitally important to know the outcomes of these other 1,554 patients as well.  237 
men underwent a full urologic workup without the finding of cancer, and such a workup is not without its 
harms (see key question 5).  Additionally, it is possible that patients not among the 21 initially diagnosed 
could have later developed bladder cancer.  It is important to know the outcomes of the screened group as 
a whole in order to assess the efficacy of screening, as there are certainly harms inherent to both screening 
(key question 3) and urologic workup.   
Furthermore, the study was based on a group of volunteers, making it susceptible to selection 
bias.  The group that declined to be screened was found to be significantly less healthy overall and had a 
higher prevalence of serious urologic diseases than the screened group.  Therefore, the finding of less 
advanced bladder cancers among the screened group is not surprising.  There were also key differences 
between the screened group and the control group from the cancer registry which could potentially be 
confounders: the screened patients had higher income, more formal education, and lower rates of 
smoking.  The study also suffers from a lack of data on compliance and drop-outs.  Finally, the positive 
predictive value of 8.1% is very low, even in this targeted population of older males. 
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Overall, we rated the internal validity of this study as “poor”.  There are significant issues with 
selection bias and lead-time bias, as well as a lack of data on the screened group as a whole.  External 
validity was rated as “fair”, as men over age 50 comprise our target population; however, this population 
may not be representative of all men in the US over age 50 as it was composed solely of volunteers.  
Again, as in the study by Britton, it is difficult to draw any conclusions of benefit from this study.  We 
rated the overall study quality as “poor”.  Please see table 5 below for a condensed description of these 
two studies. 
 
Table 5 – Characteristics of included studies (Key Question 1) 
Reference Britton 1998 (41-44) Messing 1995 (45-50) 
Research design Prospective, noncontrolled screening 
trial 
Nonrandomized controlled trial 
Location 5 general practices in Leeds, England 4 general practices in Madison, WI 
Screening test used Hemoglobin dipstick Hemoglobin dipstick 
Frequency of  
testing/Protocol 
Men > 60 years old tested first time w/ 
Multistix 10SG at clinic 
Subjects then tested at home with 
Hemastix once a week x 10 weeks 
(1,604 men) or once a day x 10 days 
(752 men)  
All with hematuria at any time offered 
full urologic workup, including 
cystoscopy 
Men > 50 years old tested at home 14 
days daily, then repeat this in 9 months 
if all tests in first 14 days were negative 
All with hematuria offered full urologic 
workup, including cystoscopy 
Total participants, 
N 
2,356 1,575 
Mean age NR Screened: 64.8 +/- 8.3 
Unscreened: 64.0 +/- 9.1 
Gender All male All male 
Duration of follow 7 years (for those diagnosed initially), Minimum 14 years in screened group 
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up no data for rest of cohort (for those diagnosed initially) 
Invited for 
screening, N 
3,152 3,515  
% screened 74.7% 44.8% 
Controls, N None 509  
Control makeup N/A All men over age 50 with BC reported 
to the Wisconsin cancer reporting 
system (WCRS) in 1988 
Initial 
comparability of 
groups 
n/a Unscreened group more likely to 
currently smoke, less likely to have 
graduated from college, had lower 
income.  Otherwise comparable 
 
Those who declined participation were 
significantly less healthy, had a higher 
prevalence of serious urologic diseases 
Potential for 
selection bias (low, 
moderate, high) 
High High 
Potential for 
measurement bias 
(low, moderate, 
high) 
Low Low 
Potential for 
confounding (low, 
moderate, high) 
High High 
Internal validity 
grade (good, fair, 
poor) 
Poor Poor 
External validity 
grade (good, fair, 
poor) 
Fair Fair 
Overall study 
quality grade (good, 
fair, poor) 
Poor Poor 
Positive test results 474 (20%) (319 agreed to undergo 258 (16.4%) 
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in screened, N (%) urologic workup) 
Bladder cancer 
found in screened, 
N (%) 
17 (0.7%) 21 (1.3%) 
PPV 3.6% (if using 17/474), 5.3% (if using 
17/319) 
8.1% 
Stage/grade of 
identified tumors 
pTa grade 1: 8 
pTa grade 2: 0 
pT1 grade 1: 1 
pT1 grade 2: 7 
Carcinoma in situ: 1 
Screened: 
- 11 (52.4%) LGN (1,2 and 
Ta,T1) 
- 9 (43%) HGN (3 and Ta,T1,Tis) 
- 1 (4.8%) Invasive (T2-T4 or N+ 
or M+) 
Unscreened: 
- 309 (60%) LGN  
- 80 (16%) HGN 
- 120 (24%) Invasive 
Bladder cancer-
specific mortality 
 
Three deaths in bladder cancer-
diagnosed group 
 
Among those with cancers detected by 
screening: 0/21 
Among controls: 104/509  
(p = .02) 
Duration of follow-
up 
7 years 14 years 
All-cause mortality 6 total deaths among those with 
bladder cancer diagnosed by screening 
Among those with screening-detected 
cancers: 9/21 
Among controls: 273/509 
(p < .004) 
Morbidity 4 with recurrences, 5 with progression 
to invasive disease 
Not reported 
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Synthesis of the evidence 
After analysis of the only two trials of screening for bladder cancer that have reported longitudinal data, it 
is clear that there is no consensus on the effect of screening on bladder cancer-specific morbidity and 
mortality.  Both studies found a very small number of cancers (17 and 21 for Britton and Messing, 
respectively), and outcomes for these cases differed by study.  None of the patients in this group in the 
Messing study have died of bladder cancer after 14 years of follow-up.  In contrast, three of the patients in 
this group in the Britton study had died of bladder cancer after seven years of follow-up, five more had 
progressed to invasive disease, and four had experienced recurrences.  The results from these two studies 
seem to be at odds with each other.  Results for each can be explained by weaknesses inherent to the 
studies. 
 Both studies found a lower percentage of invasive disease at screening than that found in ecologic 
data.  This could potentially be entirely explained by length-time bias, or screening could have truly 
picked up prevalent disease that was bound to eventually become invasive.  The lack of a control group 
makes any interpretation of the Britton data very difficult.  Similarly, the comparison group for the 
Messing study is inadequate, as it is not appropriate to compare survival between those diagnosed 
clinically and those diagnosed by screening.  The apparent mortality benefit could be completely due to 
lead-time bias, or it could be a true benefit.  Furthermore, both studies only presented data for the group 
of patients diagnosed with bladder cancer, as opposed to the entire cohort of screened patients.  The 
efficacy of a screening program must be evaluated on the basis of the outcomes for all patients who are 
screened, not merely those who are diagnosed with cancer by screening.   
The overall quality of the evidence on the effect of screening on morbidity and mortality is poor.  
Additionally, the results from these poor studies conflict with each other.  Therefore, we have insufficient 
evidence to answer key question 1, “Does screening for bladder cancer lead to decreased morbidity or 
mortality?” 
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Key Question 2 
 
Hemoglobin Dipstick 
Over-the-counter hemoglobin dipsticks (Hemastix; Bayer, Pittsburgh, PA) are a simple and inexpensive 
method of detecting microhematuria (64).  Their proper use requires little training, and they can be used 
in the physician‟s office or in the patient‟s home. They are very inexpensive, averaging 25 cents a test 
(56).  For these reasons, hemoglobin dipsticks represent an attractive candidate for a screening modality. 
 
Search Results 
Performance of our search for studies of the diagnostic accuracy of hemoglobin dipsticks through 
MEDLINE, EMBASE, and the Cochrane database, in addition to review of reference lists yielded an 
initial total of 129 articles.  Of these, we excluded 85 citations that were clearly not related to our study 
question based on title review.  Thus, 44 citations were available for abstract review.  Of these, two were 
excluded that were published solely in abstract form.  On abstract review, 13 studies were excluded that 
did not meet our eligibility criteria.  Specifically, these studies all included  measurement of recurrence of 
bladder cancer, as opposed to primary disease, as the type of cancer being detected.  This left 29 articles 
for full-text review.   
 Of the 29 articles reviewed in full-text form, 14 were excluded on the basis of being review 
articles.  An additional 12 articles were excluded because they did not meet our eligibility criteria.  
Specifically, five studies were excluded because they did not present enough information to construct a 
2x2 table; these studies reported only sensitivity or specificity, but not both.  Eight further articles were 
excluded because they measured the diagnostic accuracy of hemoglobin dipstick for recurrent bladder 
cancer, not primary disease.  This left two articles for analysis that met all of our eligibility criteria.  They 
are described in detail below.  Please see figure 2 below for a flow chart of included and excluded 
articles. 
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Figure 2.  Flow chart of included and excluded studies, Key Question 2, Hemoglobin Dipstick 
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Description of Included Studies 
In a 2003 study, Bhuiyan and colleagues (53) prospectively enrolled 233 patients under suspicion for 
bladder cancer for a study of the diagnostic accuracy of hemoglobin dipsticks, BTA stat, and NMP22.  A 
case-control study design was used, wherein all patients received cystoscopy (the reference standard) as 
well as testing of their urine for the three aforementioned markers.  70 patients were found to have 
transitional cell carcinoma (TCC) of the bladder, and 163 patients were found to have other urological 
conditions.  These 163 patients served as controls.  The reported sensitivity of hemoglobin dipsticks for 
bladder cancer was 47%, and the specificity was 82%.  Positive predictive value (PPV) was found to be 
55%, and negative predictive value was 78%. 
 This study has a number of weaknesses which make it difficult to draw conclusions from these 
figures, especially for our target population and purpose.  The authors do not report demographic data for 
the participants, so we do not know if a wide spectrum was obtained.  The authors also do not report 
whether test interpretation (both index and reference) was blinded, and the cutoff value used for a 
“positive” dipstick is not defined.  Furthermore, the authors do not report whether patient selection was 
consecutive, random, or non-random, introducing a source of potential selection bias.  We gave the 
overall internal validity of this study a “poor” grade.  External validity is also limited in that the study 
used urologic patients instead of a targeted primary care population.  We gave the external validity of the 
study a “poor”, in spite of the fact that hemoglobin dipsticks are easy to administer, widely available and 
very cheap, due to the dissimilarity between this population and our target population.  This dissimilarity 
certainly limits the generalizability of the results.  Use of a urological population likely affected the PPV 
and NPV strongly; the PPV in an asymptomatic, non-urologic population would likely be much lower 
than 55%.  We gave this study an overall score of “poor”. 
 In a similar case-control design, Saad and colleagues also studied the diagnostic accuracy of 
hemoglobin dipsticks, NMP22, and BTA stat (55).  120 patients with “various urological conditions” 
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were recruited before receiving surgery.  The distribution of these diseases is not reported.  All patients 
received cystoscopy and histopathology as the reference standard.  Mean age of the cohort was 69.5 years 
old, with men comprising 83% of the sample and women comprising 17%.  Of these 120 patients, 52 
were found to have bladder cancer on cystoscopy.  The remaining 68 served as controls.  A positive result 
on hemoglobin dipstick was defined as hemolyzed trace or greater.  The authors report a sensitivity of 
50%, a specificity of 54%, a PPV of 46%, and a NPV of 59%.  Of note, the test was statistically more 
sensitive and specific as the grade and stage of tumors increased. 
 Like the study by Bhuiyan, this study also has several glaring weaknesses.  While the authors do 
at least report the mean age of the sample as well as the gender distribution, the article lacks any other 
demographic information, including ethnicity and comorbid conditions.  Without a clear description of 
the study population, assessment of the internal validity is difficult.  The authors did not report whether 
the participants were accepted into the study consecutively, randomly, or neither, introducing the potential 
for selection bias.  These two factors led us to grade the internal validity of this study as “poor”.  External 
validity was once again grade as “poor”.  Although the test itself has desirable characteristics for a 
screening test, as mentioned above, the extremely high-risk urologic population used in this study limits 
its generalizability.  The overall study quality was rated as “poor”.  Please see table 6 below for a 
condensed description of these two studies. 
 
Table 6 – Characteristics of included studies (Key Question 2, Hemoglobin Dipstick) 
Reference Bhuiyan 2003 (53) Saad 2002 (55) 
Study Design Case-control Case-control 
Index test Hemoglobin dipstick Hemoglobin dipstick 
Reference Standard Cystoscopy Cystoscopy and histopathology 
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Location NR UK 
Total Participants, N 233 120 
Description of 
participants/exclusions 
All participants under suspicion of BC 
 
Cases: 70 patients with TCC 
Controls: 163 urological patients 
Patients with various urological 
conditions recruited before receiving 
urological surgery 
 
52 had bladder cancer, 68 had other 
urological diseases 
Mean age NR 69.5 
Gender NR 100 men, 20 women 
Index test cutoff used NR Hemolyzed trace or greater 
Reference standard 
always performed? 
Yes Yes 
Test interpretation 
blinded? 
NR Yes 
Consecutive selection of 
patients, random 
selection, or neither? 
NR NR 
Wide spectrum of patients 
included? 
NR NR 
Sufficient description of 
test protocol? 
Yes Yes 
Industry sponsorship No No 
Overall internal validity 
grade (good, fair, poor) 
Poor Poor 
Similarity of study 
population to primary 
care population (1 = very 
similar, 2 = moderate 
similarity, 3 = dissimilar) 
3 3 
Availability of test Widely available Widely available 
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Ease of administration 
(easy, moderate, difficult) 
Easy Easy 
Cost per test (58) $0.25 $0.25 
Overall external validity 
grade (good, fair, poor) 
Poor Poor 
Overall study quality 
grade (good, fair, poor) 
Poor Poor 
Sensitivity 47% 50% 
Specificity 82% 54% 
Positive Predictive Value 55% 46% 
Negative Predictive Value 78% 59% 
Comments  Sensitivity increased with increasing 
grade and stage. 
NR = Not Reported, BC = Bladder Cancer, TCC = Transitional Cell Carcinoma 
Synthesis of the evidence 
Performance of our search resulted in only two studies that met our eligibility criteria.  Sensitivity of 
hemoglobin dipstick for bladder cancer in the included studies ranged from 47% to 50%.  Specificity 
ranged from 54% to 82%.  Taken as truth, these results would seem to indicate that testing for hematuria 
is neither sensitive nor specific enough for screening purposes in an asymptomatic, primary care 
population.  The lack of a high sensitivity indicates that there would be a high number of false negative 
results, which is unacceptable in a screening program.  PPV in these two studies ranged from 46% to 
55%, meaning a large number of patients would undergo needless and expensive confirmatory testing.  
Furthermore, the PPV is likely to actually be much lower than these figures.  Studies performed in 
populations with a very high prevalence of disease will result in an inflated PPV.  As proof, four of our 
excluded studies came from screening trials (35, 36, 41-50); the PPV in these studies ranged from 3-8%.  
These studies were performed on populations of older men, and were not limited to urologic patients.  
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This lower estimate of PPV is likely much more accurate, and is a further indication that screening by 
way of hemoglobin dipstick would result in unnecessary testing in the vast majority of patients who test 
positive. 
 The overall body of evidence for the diagnostic accuracy of dipstick testing for primary bladder 
cancer is weak.  Only two studies met inclusion criteria, and both were rated overall as poor quality.  
Therefore, it would be unwise to rely on the results of these studies as representing the true test 
characteristics of urine dipsticks in our target population.  Before any recommendation of a widespread 
screening program utilizing this test modality, it is important that studies be performed in populations that 
better represent a primary care population, and the studies should more closely consider sources of bias in 
studies of diagnostic accuracy as defined by Whiting and colleagues (27).  In the event that such studies 
are performed, they would need to show a substantially better sensitivity, specificity and PPV for this test 
to be considered.  Hemoglobin dipstick testing is an attractive candidate for a screening modality due to 
its low cost, widespread availability, and ease of administration, but cannot be recommended as such at 
this time. 
 
Urine Cytology 
Perhaps the most established noninvasive work-up of hematuria and follow-up of patients with a history 
of bladder cancer can be found in cytology of tumor cells exfoliated into voided urine or bladder washes 
(64).  Examination of cells is dependent on the interpretation of a pathologist, and turn-around time can 
be 24 hours or more.  The cost of the test is also relatively high, at $57 dollars per test. 
Search Results 
Performance of our search for studies of the diagnostic accuracy of urine cytology through MEDLINE, 
EMBASE, and the Cochrane database, in addition to review of reference lists yielded an initial total of 
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336 articles.  Of these, we excluded 217 citations that were clearly not related to our study question based 
on title review.  Thus, 119 citations were available for abstract review.  Of these, four were excluded that 
were published solely in abstract form.  On abstract review, 64 studies were excluded that did not meet 
our eligibility criteria.  This left 51 articles for full-text review.   
 Of the 51 articles reviewed in full-text form, 17 were excluded on the basis of being review 
articles.  An additional 25 articles were excluded because they did not meet our eligibility criteria.  
Specifically, six studies were excluded because they did not present enough information to construct a 
2x2 table; these studies reported only sensitivity or specificity, but not both.  Nineteen further articles 
were excluded because they measured the diagnostic accuracy of cytology for recurrent bladder cancer, 
not primary disease.  This left nine articles for analysis that met all of our eligibility criteria, consisting of 
eight observational studies and one systematic review.  They are described in detail below.  Please see 
figure 3 below for a flow chart of included and excluded articles. 
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Figure 3.  Flow chart of included and excluded studies, Key Question 2, Cytology 
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Description of included studies 
We found 9 articles reporting sensitivity and specificity for cytology that ultimately met our inclusion 
criteria, including 8 observational studies and one systematic review.  Two of these studies have been 
described above, as they also tested hemoglobin dipsticks (53, 55).  Briefly, both studies (conducted by 
Bhuiyan and Saad) were case-controls conducted with urological patients under suspicion for bladder 
cancer.  Sensitivity and specificity of cytology in the Bhuiyan study were 40% and 95%, respectively.  
PPV and NPV were 90% and 58%.  In the Saad study, sensitivity and specificity were 52% and 87%, and 
PPV and NPV were 74% and 69%.  Of note, sensitivity in this study increased with increasing grade and 
stage of tumor.  As previously described, both studies had numerous problems, decreasing both internal 
and external validity, and both were rated as poor quality evidence. 
 In a 2002 study conducted in Sweden, Boman and colleagues tested 156 patients who all had 
microhematuria for bladder cancer by using urine cytology (54).  Confirmatory cystoscopy was 
performed in all patients.  Of these 156 patients, 92 were found to have bladder cancer by cystoscopy, 
whereas 64 had a negative cystoscopy and were included as controls.  Of note, 302 patients were 
originally sought to be included in the bladder cancer group.  However, due to a variety of reasons (such 
as being in “too poor a condition to participate”), they were excluded.  Therefore, the selection of patients 
was neither consecutive nor random.  The authors report a sensitivity of 42%, a specificity of 96%, a PPV 
of 94%, and a NPV of 55%.  This study is weakened by a number of weaknesses shared with the previous 
two studies.  Demographic data is extremely limited beyond mean age and gender.  We do know that all 
patients were being evaluated for microhematuria, and that there was a list of exclusion criteria consisting 
of comorbid cancer or urological conditions (see table 7).  However, this reinforces the limited spectrum 
of patients tested.  Selection of patients was certainly not consecutive or random, as only 92 of the 
original 302 patients with bladder cancer sought for participation (30%) were tested.  This introduces a 
large potential for selection bias.  The overall internal validity for this study was rated as poor, as was its 
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external validity.  Use of such a restricted (even among urologic populations) sample severely limits this 
study‟s generalizability.  PPV is once again likely to be much lower in a screened population than 
reported here.  Overall, we rated this study as poor quality evidence. 
 In a 2005 study, Grossman and colleagues used a cohort design to test 1,331 consecutive patients 
with risk factors for or symptoms of bladder cancer with urine cytology (57).  All patients underwent 
confirmatory cystoscopy.  26 patients with negative cystoscopy were found to have active cancer at 
another site; these patients served as the control group.  Patients came from 22 geographically dispersed 
sites in 10 different states.  Mean age was 59 years old, and the sample was comprised of 57% men and 
43% women.  The reference standard was always performed, test interpretation was blinded, a 
consecutive series of patients was selected, and a wide spectrum of patients was included.  The study also 
tested the diagnostic accuracy of NMP22, and the study was sponsored by Matritech Inc. of Cambridge, 
Massachusetts, producers of the NMP22 assay.  Overall sensitivity and specificity of cytology in this 
study were found to be 15.8% and 99.2%, respectively.  PPV and NPV were 54.6% and 94.9%.  „ 
This study managed to avoid many of the pitfalls inherent to the other included studies.  It 
adhered to guidelines for studies of diagnostic accuracy.  We gave this study a grade of “good” for 
internal validity.  Although it was sponsored by the manufacturer of one of the tests being studied, it 
appears to have paid close attention to those factors that could affect the internal validity of the study, and 
avoided them.  We also gave the external validity a grade of “good”.  A wide variety and comparatively 
large number of patients were included, and they were similar to a potential targeted screening population 
of primary care patients who may have symptoms or risk factors for bladder cancer.  We gave this study 
an overall grade of “good”, and found it to perhaps be the strongest evidence available for the diagnostic 
accuracy of cytology and NMP22. 
In 2002, Eissa and colleagues  used a case-control design to test “consecutive patients admitted to 
the urology department” at their hospital in Egypt for bladder cancer by way of cytology (58).  215 
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patients were included, and all received confirmatory cystoscopy and biopsy.  These patients were divided 
into three groups: a malignant group (n=100), a benign group (n=68), and a normal group (n=47).  
Demographic characteristics for included patients were not provided.  The selection of patients was 
consecutive, and the reference standard was always performed.  We could not determine from the article 
if test interpretation was blinded, nor could we determine whether a wide spectrum of patients was 
included.  Sensitivity, specificity, PPV and NPV were reported as 44%, 100%, 100%, and 67%, 
respectively.  A lack of information on the included patients and their need to be admitted to the urology 
department of a hospital weakens the internal validity of this study.  Furthermore, we are not told whether 
test interpretation was blinded.  We gave the overall internal validity of this study a grade of “poor”.  We 
also gave a grade of “poor” for its external validity as a result of the very specific urologic population 
used and its lack of generalizability to an asymptomatic screening population.  Our overall study grade 
was “poor”.   
Melissourgos and colleagues used a total of 174 patients in a 2003 case-control study to 
determine the diagnostic accuracy of urine cytology (59).  Cystoscopy and biopsy were used as the 
reference standard.  The overall sample of 174 patients was divided into three groups: 146 patients with 
newly diagnosed bladder cancer, 51 healthy volunteers serving as controls, and 77 patients with 
nonmalignant urinary disease also serving as controls.  Of importance, cystoscopy was only performed in 
a subset of controls.  A random selection of controls with positive cytology or telomerase (the other 
biomarker being studied) tests were chosen to undergo cystoscopy.  Futhermore, there is a lack of 
information on the blinding of test interpretation and how the patients were chosen.  The study was 
sponsored by the test manufacturer Pharmacia & Upjohn Inc. (Sweden).  Sensitivity of cytology was 
reported as 43.8%, and specificity was 96.9%.  PPV was 94.1%, and NPV was 60.2%.  Like most of the 
other included studies, there were a large number of methodological flaws in this study that limit our 
ability to draw conclusions from it.  The first is the differential application of the reference standard to the 
control group, a case of partial verification bias.  Further, there is not a wide spectrum of patients 
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included, and we do not know anything about selection of patients and test interpretation.  The internal 
validity was hence rated as “poor”.  External validity was also rated as “poor” due to the urologic nature 
of the population, and the overall study quality was similarly rated as “poor”. 
Marin-Aguilera and colleagues also used a case-control design to study the diagnostic accuracy of 
cytology and UroVysion FISH in 2007 (60).  A total of 112 patients were tested, which were divided into 
three groups: 74 patients with superficial TCC, 19 patients with muscle-invasive disease, and 19 healthy 
controls.  Recruitment and selection of these patients are not discussed.  Demographic information is also 
not reported.  Cystoscopy served as the reference standard, although the authors do not report if it was 
performed among the healthy control group.  Test interpretation was blinded, but we could not determine 
if patient selection was consecutive, random or neither.  Sensitivity, specificity, PPV and NPV were 
reported as 35.1%, 100%, 100%, and 28% respectively.  We gave this study‟s internal validity a grade of 
“poor” for a number of familiar reasons.  Characteristics of the included patients are not included and 
consecutive patients may or may have been used.  Further, the reference standard may have been 
unequally applied between groups.  We again rated external validity as “poor” due to the specific urologic 
nature of the population.  Once again, overall study quality was “poor”. 
In our last included observational study, Sanchez-Carbayo and colleagues studied 187 patients in 
a case-control design (61).  Cystoscopy was used as the reference standard and was performed among all 
patients.  The sample was divided into two groups: group one contained 112 subjects who were under 
suspicion of bladder cancer due to microhematuria, and group two consisted of 75 patients with other 
urological diseases that might simultaneously appear in those with bladder cancer.  We could not 
determine whether a consecutive or random selection of patients had been used, or neither.  A wide 
spectrum of disease does not appear to have been represented.  Test interpretation was blinded.  In this 
study, sensitivity of cytology was reported as 35.4%, specificity was 97.2%, PPV was 85.2% and NPV 
was 72.5%.  Internal validity for this study, like those before it, was rated as “poor” due to a lack of 
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information on the spectrum of disease of the patients, as well as the lack of information on how these 
patients were chosen.  Again, external validity was rated as “poor” due to a lack of generalizability, and 
overall study quality was “poor”.  See table 7 below for a condensed description of the 8 included 
observational studies. 
Our search of the literature yielded one systematic review and meta-analysis that looked at 
markers for diagnosis of primary bladder cancer (63).  In this 2003 study, Glas and colleagues performed 
a comprehensive and well-described search of the literature spanning January 1990 through December 
2001.  Among our tests of interest, they searched for studies of diagnostic accuracy for cytology, NMP22, 
and BTA stat.  They required each study to make a diagnosis of primary, as opposed to recurrent, bladder 
cancer.  The review was based on a focused clinical question, and the authors used a standard method to 
appraise the internal validity of the included studies.  These appraisals were performed by two authors.  
The review assessed and explained heterogeneity, and used sound statistical methods to perform a meta-
analysis for each marker, making a composite score for sensitivity and specificity (PPV and NPV were 
not assessed).  The authors identified 26 articles that met their inclusion criteria and tested urine cytology.  
This represents 3,444 total patients.  Their summary sensitivity score for cytology was 55%, and 
specificity was 94%.   
This systematic review was very well-done, meeting the vast majority of suggestions for 
reporting systematic reviews as outlined by the PRISMA statement (51).  As such, we rated the overall 
quality of this study as “good”.  However, the authors note that the overall quality of the studies included 
in their analysis was weak.  Specifically, among all included studies (n=42), only 40% had a clear 
description of patient demographics, 7% had a clear description of the reference standard and who 
received it, 33% had blinded interpretation of test results, and 11% used consecutive samples.  These 
figures are qualitatively in line with the quality of studies identified in our own search.  While the review 
itself was very well done, our ability to draw conclusions from it is tempered by the poor quality of the 
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included studies.  As a review that used sound statistical methods, though, it is likely to contain more 
valid estimates of sensitivity and specificity than any of the individual studies.  For a condensed 
description of the characteristics of this study, see table 8 below. 
Table 7 – Characteristics of included observational studies (Key Question 2, Cytology) 
Reference Bhuiyan 2003 (53) Saad 2002 (55) Boman 2002 (54) 
Study Design  Case-control Case-control Case-control 
Index test Cytology Cytology Cytology 
Reference Standard Cystoscopy Cystoscopy and 
histopathology 
Cystoscopy 
Total Participants, N NR UK Sweden 
Location 233 120 156 
Description of 
participants/exclusions 
All participants under 
suspicion of BC 
 
Cases: 70 patients with 
TCC 
Controls: 163 urological 
patients 
Patients with various 
urological conditions 
recruited before receiving 
urological surgery 
 
52 had bladder cancer, 68 
had other urological 
diseases 
All participants were being 
evaluated for 
microhematuria. 
 
Cases: 92 BC patients 
Controls: 64 patients 
evaluated for 
microhematuria with 
negative cystoscopy. 
 
Exclusions: prostate CA, 
renal CA, UTI, stones, 
indwelling catheter 
 
Note: 302 patients with 
BC originally sought, only 
92 participated  
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Mean age NR 69.5 Cases: 71 
Controls: 52 
Gender NR 100 men, 20 women Cases: 67 men, 25 women 
Controls: NR 
Index test cutoff used NR NR NR 
Reference standard 
always performed? 
Yes Yes Yes 
Test interpretation 
blinded? 
NR Yes Yes 
Consecutive selection 
of patients, random 
selection, or neither? 
NR NR Neither 
Wide spectrum of 
patients included? 
NR NR No 
Sufficient description 
of test protocol? 
Yes Yes Yes 
Industry sponsorship No No No 
Overall internal 
validity grade (good, 
fair, poor) 
Poor Poor Poor 
Similarity of study 
population to primary 
care population (1 = 
very similar, 2 = 
moderate similarity, 3 
= dissimilar) 
3 3 3 
Availability of test Widely available Widely available Widely available 
Ease of administration 
(easy, moderate, 
difficult) 
Difficult – requires 
interpretation of 
pathologist, turn-around is 
24 hours or more 
Difficult – requires 
interpretation of 
pathologist, turn-around is 
24 hours or more 
Difficult – requires 
interpretation of 
pathologist, turn-around is 
24 hours or more 
Cost per test (58) $57 $57 $57 
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Overall external 
validity grade (good, 
fair, poor) 
Poor Poor Poor 
Overall study quality 
grade (good, fair, 
poor) 
Poor Poor Poor 
Sensitivity 40% 52% 42% 
Specificity 95% 87% 96% 
Positive Predictive 
Value 
90% 74% 94% 
Negative Predictive 
Value 
58% 69% 55% 
Comments  Sensitivity increased with 
increasing grade and stage. 
Sensitivity increased with 
increasing grade and stage. 
 
Reference Grossman 2005 (57) Eissa 2002 (58) Melissourgos 2003 (59) 
Study Design  Cohort Case-control Case-control 
Index test Cytology Cytology Cytology 
Reference Standard Cystoscopy with biopsy Cystoscopy with biopsy Cystoscopy with biopsy 
Total Participants, N 1,331 215 174 
Location 22 geographically 
dispersed sites in 10 
states 
Egypt Greece 
Description of 
participants/exclusions 
Test group: 1,305 
consecutive patients 
with BC risk factors or 
symptoms (smoking, 
hematuria, dysuria) 
 
Exclusions: hx of BC 
“Consecutive patients 
admitted to the urology 
department” 
 
 
Divided into: 
Cases: 146 patients w/ newly 
diagnosed BC 
 
 
Controls (128 total): 51 
healthy volunteers, 77 
nonmalignant urinary 
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Controls: 26 patients w/ 
active malignancies 
(other than bladder) to 
determine specificity 
 
- malignant group (100) 
- benign group (68), and 
- normal group (47 healthy 
volunteers) 
disease 
Mean age 58.7 Malignant group: 56.5 
Benign: 45 
Normal: 37 
NR 
Gender 57% male, 43% female NR NR 
Index test cutoff used Malignant or dysplastic 
cells present 
NR NR 
Reference standard 
always performed? 
Yes Yes No – random biopsies 
performed in those with a 
positive result (among 
controls) 
Test interpretation 
blinded? 
Yes NR NR 
Consecutive selection 
of patients, random 
selection, or neither? 
Consecutive Consecutive NR 
Wide spectrum of 
patients included? 
Yes Yes No 
Sufficient description 
of test protocol? 
Yes Yes Yes 
Industry sponsorship Matritech Inc. 
(Cambridge, MA – 
producer of NMP22) 
No Pharmacia Upjohn Co. 
Overall internal 
validity grade (good, 
fair, poor) 
Good Poor Poor 
Similarity of study 2 3 3 
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population to primary 
care population (1 = 
very similar, 2 = 
moderate similarity, 3 
= dissimilar) 
Availability of test Widely available Widely available Widely available 
Ease of administration 
(easy, moderate, 
difficult) 
Difficult – requires 
interpretation of 
pathologist, turn-around 
is 24 hours or more 
Difficult – requires 
interpretation of 
pathologist, turn-around is 
24 hours or more 
Difficult – requires 
interpretation of pathologist, 
turn-around is 24 hours or 
more 
Cost per test (58) $57 $57 $57 
Overall external 
validity grade (good, 
fair, poor) 
Good Poor Poor 
Overall study quality 
grade (good, fair, 
poor) 
Good Poor Poor 
Sensitivity 15.8% 44% 43.8% 
Specificity 99.2% 100% 96.9% 
Positive Predictive 
Value 
54.6% 100% 94.1% 
Negative Predictive 
Value 
94.9% 67% 60.2% 
Comments   Sensitivity increased with 
increasing grade 
 
Reference Marin-Aguilera 2007 
(60) 
Sanchez-Carbayo 2001 (61) 
Study Design  Case-control Case-control 
Index test Cytology Cytology 
Reference Standard Biopsy Cystoscopy 
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Total Participants, N 112 187 
Location Spain Spain 
Description of 
participants/exclusions 
G1: 74 superficial TCC 
G2: 19 muscle-invasive 
controls 
G3: 19 healthy controls 
G1: 112 subjects who 
were to undergo cystoscopy 
for a microhematuria 
suspicious 
for a primary bladder tumor 
 
G2: 75 patients with other 
common urological 
diseases that might 
simultaneously appear in 
those with bladder cancer 
Mean age NR G1: 65.5 
G2: 69 
Gender NR G1: 87 male, 25 female 
G2: 49 male, 26 female 
Index test cutoff used Positive, negative or 
suspicious (suspicious 
classified as negative) 
NR 
Reference standard 
always performed? 
Yes, but not reported for 
healthy controls 
Yes 
Test interpretation 
blinded? 
Yes Yes 
Consecutive selection 
of patients, random 
selection, or neither? 
NR NR 
Wide spectrum of 
patients included? 
Could not determine No 
Sufficient description 
of test protocol? 
Yes Yes 
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Industry sponsorship No No 
Overall internal 
validity grade (good, 
fair, poor) 
Poor Poor 
Similarity of study 
population to primary 
care population (1 = 
very similar, 2 = 
moderate similarity, 3 
= dissimilar) 
2 3 
Availability of test Widely available Widely available 
Ease of administration 
(easy, moderate, 
difficult) 
Difficult – requires 
interpretation of 
pathologist, turn-around 
is 24 hours or more 
Difficult – requires 
interpretation of 
pathologist, turn-around is 
24 hours or more 
Cost per test (58) $57 $57 
Overall external 
validity grade (good, 
fair, poor) 
Poor Poor 
Overall study quality 
grade (good, fair, 
poor) 
Poor Poor 
Sensitivity 35.1% 35.4% 
Specificity 100% 97.2% 
Positive Predictive 
Value 
100% 85.2% 
Negative Predictive 
Value 
28% 72.5% 
Comments Sensitivity increased for 
increasing grade and 
stage 
 
NR = Not Reported, BC = Bladder Cancer, TCC = Transitional Cell Carcinoma 
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Table 8 – Characteristics of included systematic review, Key Question 2, cytology 
Reference Glas 2003 (62) 
Year 2003 
Design (SR and/or meta-analysis) Both 
Study designs included Cohort, case-control 
Time period covered January 1990 – December 2001 
Characteristics of included studies - Incorporated at least 1 target marker 
- Detection in urine 
- Sensitivity and specificity were the outcome 
measures 
- Cystoscopy and/or histopathology used as 
reference standard 
- Enough information to draw a 2x2 contingency 
table 
- Included a per-patient analysis 
- Made a diagnosis of primary bladder cancer 
 
 
Characteristics of included 
populations 
3,444 patients for cytology 
Characteristics of interventions NMP22, BTA stat, cytology 
Main results Cytology:  
- Sensitivity = 55% (48-62) 
- Specificity = 94% (90-96) 
Adverse events NR 
Was the SR based on a focused 
clinical question? 
Yes 
Was a comprehensive literature 
search strategy used? 
Yes 
Did the SR use a standard method 
of to appraise the internal validity of 
Yes 
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included studies? 
Was publication bias assessed? No 
Did the SR assess and explain 
heterogeneity? 
Yes 
Was the statistical analysis 
appropriate? 
Yes 
Quality rating (good, fair, poor) Good 
 
Synthesis of the evidence 
Performance of our search resulted in 8 observational studies and one systematic review/meta-analysis 
that met our inclusion criteria.  Reported sensitivity in these 9 studies ranged from 15.8% to 52%.  Not 
surprisingly, the low end of this figure comes from the one study that was performed in a general practice 
population, that by Grossman et al (57).  The pooled sensitivity estimate from the systematic review was 
55%, which is reflective of the urologic populations that made up the vast majority of included 
publications.  Specificity in our included studies ranged from 87% to 100%, with an estimate of 94% 
from the systematic review.  While the quality of the included studies was overall poor, it is likely that 
cytology is indeed a very specific test for bladder cancer.  PPV ranged from 54.6% (in the Grossman 
study) to 100%.  The figure of 54.6% is therefore much more applicable to our targeted screening 
population.  NPV ranged from 28% to 94.9%, an extremely wide range which may simply be indicative 
of the overall poor internal validity of most of the included studies. 
 The overall body of evidence for the diagnostic accuracy of cytology for bladder cancer is weak.  
With that in mind, the sensitivity of the test in these studies has been shown to be very low, with the most 
optimistic estimates being around 55%.  This sensitivity would be unacceptable for a screening program.  
Notably, several of the studies commented that there was a statistically significant increase in sensitivity 
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as the grade and stage of cancers increased.  However, this does not make cytology a more attractive 
candidate for screening, as we would be more interested in picking up the lower grade and stage tumors 
before they have the potential to invade muscle.  The specificity of the test is admirable and would be 
well-suited for screening.  However, the (most likely) low PPV would create the possibility of a large 
amount of needless confirmatory testing.  We cannot recommend urine cytology as a screening modality 
at this time, although the body of evidence for its diagnostic accuracy could certainly be vastly improved. 
 
Nuclear Matrix Protein-22 (NMP22) 
Nuclear matrix proteins (NMPs) serve as a scaffold in the nucleus and help regulate mitosis (64).  NMP22 
is overexpressed in bladder tumors and released into the urine following apoptosis of tumor cells.  Testing 
for NMP22 (Matritech, Cambridge, MA) is approved by the US Food and Drug Administration for 
surveillance and screening for bladder cancer.  Performance of NMP22 is relatively simple, as it is a 
point-of-care test, with results available within 30 to 50 minutes.  Cost of the test is relatively cheap at 
$13.50 per test (56).  For these reasons, NMP22 may be attractive as a screening test for primary bladder 
cancer. 
Search results 
Performance of our search for studies of the diagnostic accuracy of NMP22 through MEDLINE, 
EMBASE, and the Cochrane database, in addition to review of reference lists yielded an initial total of 
111 articles.  Of these, we excluded 51 citations that were clearly not related to our study question based 
on title review.  Thus, 60 citations were available for abstract review.  Of these, three were excluded that 
were published solely in abstract form.  On abstract review, 26 studies were excluded that did not meet 
our eligibility criteria.  This left 31 articles for full-text review.   
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 Of the 31 articles reviewed in full-text form, 10 were excluded on the basis of being review 
articles.  An additional 13 articles were excluded because they did not meet our eligibility criteria.  
Specifically, three studies were excluded because they did not present enough information to construct a 
2x2 table; these studies reported only sensitivity or specificity, but not both.  Ten further articles were 
excluded because they measured the diagnostic accuracy of NMP22 for recurrent bladder cancer, not 
primary disease.  This left eight articles for analysis that met all of our eligibility criteria.  They are 
described in detail below.  Please see figure 4 below for a flow chart of included and excluded articles. 
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Figure 4.  Flow chart of included and excluded articles, Key Question 2, NMP22 
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Description of included studies 
Of the eight included studies for NMP22, seven have been discussed in detail above (many of the trials 
used more than one index test).  The one unique study for NMP22 was conducted by Chang and 
colleagues and published in 2004 (63).  In this case-control design, 399 participants were divided into 
three groups: a test group of 28 patients with biopsy-proven bladder cancer, a control group of 303 
patients without GU malignancy with other urological disorders, and another control group of 68 healthy 
volunteers.  Demographic information for these patients other than age and gender is not reported.  
Patients in the two groups with urinary disorders (including bladder cancer) received NMP22 and 
cystoscopy; however, it was not clear if patients in the healthy group always received cystoscopy, if at all.  
Test interpretation was blinded, but we are not told whether patient selection was consecutive, random, or 
neither.  Furthermore, the authors‟ description of the test protocol was insufficient.  For these numerous 
deficiencies, we gave the internal validity of this study a grade of “poor”.  We also gave the external 
validity a grade of “poor” as a result of the very specific urologic nature of the included population.  Test 
accuracy estimates were as follows: sensitivity was 35.7%, specificity was 87.4%, PPV was 20.8% and 
NPV was 93.6%.  We gave this study an overall grade of “poor”.  Please see table 9 below for a 
condensed description of this study.  
 The other seven studies that met our eligibility criteria for NMP22 include six observational 
studies and one systematic review.  The quality scores for these studies have all been described above 
under the results sections for hemoglobin dipstick and cytology.  Estimates of sensitivity, specificity, PPV 
and NPV for all studies included for NMP22 are presented below in table 10, along with their overall 
study grades.  Briefly, sensitivity ranged from 35.7% to 81%.  Estimates from the two studies rated as 
good quality were 67% (Glas) and 55.7% (Grossman).  These estimates are likely more reflective of the 
true sensitivity of this test.  Specificity among all studies ranged from 62% to 91%, with the Glas and 
Grossman studies estimating specificity at 85.7% and 78%, respectively.  PPV ranged from 19.7% to 
72 
 
82%, with Grossman estimating it at 19.7%.  Finally, NPV ranged from 67% to 97%, with Grossman 
estimating it at 96.8%.  
Table 9 – Characteristics of unique included studies, Key Question 2, NMP22 
Reference Chang 2004 (63) 
Study Design  Case-control 
Index test NMP22 
Reference Standard Cystoscopy with biopsy 
Total Participants, N 399 
Location Taiwan 
Description of 
participants/exclusions 
G1: 68 healthy participants 
 
G2: 303 patients without GU malignancy with other urological 
disorders 
 
G3: 28 patients with biopsy-proven urogenital cancer 
Mean age 52.9 (although G3 was “significantly older”) 
Gender 220 male, 111 female 
Index test cutoff used 10 U/mL 
Reference standard always 
performed? 
Yes for G2 and G3, no for G1 (healthy controls) 
Test interpretation blinded? Yes 
Consecutive selection of patients, 
random selection, or neither? 
NR 
Wide spectrum of patients included? Yes 
Sufficient description of test 
protocol? 
No 
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Industry sponsorship No 
Overall internal validity grade (good, 
fair, poor) 
Poor 
Similarity of study population to 
primary care population (1 = very 
similar, 2 = moderate similarity, 3 = 
dissimilar) 
2 
Availability of test Moderately available 
Ease of administration (easy, 
moderate, difficult) 
Easy – point of care assay 
Cost per test (58) $13.50 
Overall external validity grade 
(good, fair, poor) 
Poor 
Overall study quality grade (good, 
fair, poor) 
Poor 
Sensitivity 35.7% 
Specificity 87.4% 
Positive Predictive Value 20.8% 
Negative Predictive Value 93.6% 
Comments  
 
Table 10 – Diagnostic accuracy estimates for NMP22 for included studies 
Reference Bhuiyan 
2003 
(53) 
Boman 
2002 
(54) 
Chang 
2004 
(63) 
Eissa 
2002 
(58) 
Glas 2003 
(62) 
Grossman 
2005 
(57) 
Saad 
2002 
(55) 
Sanchez-
Carbayo 
2001 
(61) 
Study Case- Case- Case- Case- Systematic Cohort Case- Case-
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design control control control control Review control control 
Total 
participants, 
N 
233 156 399 215 2,290 1,331 120 187 
Sensitivity 61% 75% 35.7% 85% 67% 55.7% 81% 61.2% 
Specificity 62% 78% 87.4% 91.3% 78% 85.7% 87% 89.9% 
PPV 39% 80% 20.8% 89.5%  19.7% 82% 81.1% 
NPV 78% 67% 93.6% 87.5%  96.8% 86% 76.5% 
Overall 
study 
quality 
Poor Poor Poor Poor Good Good Poor Poor 
Comments  More 
sensitive 
for 
higher 
grades 
and 
stages 
 More 
sensitive 
for 
higher 
grades 
and 
stages 
 More 
sensitive 
for higher 
grades 
and 
stages 
  
 
 
Synthesis of the evidence 
Sensitivity of NMP22 for bladder cancer detection varied widely among the included studies, ranging 
from 35.7% to 81%.  Sensitivities from the two good quality studies were much closer together, 55.7% 
and 67%.  The true sensitivity is more likely to be along those lines.  As a screening test, this sensitivity 
would be unacceptably low.  A large number of prevalent bladder tumors would be missed if NMP22 
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were used on its own.  Specificity ranged from 62% to 91%, with estimates from the good quality studies 
of 78% and 87%.  If the true specificity of this test for primary bladder cancer lies on the higher end of 
this range, then this would most likely be an acceptable specificity.  A large number of false positives 
would occur, though, and would lead to unnecessary testing.  This leads us to estimates of PPV, which 
again varied widely – 19.7% to 82%.  This wide range is certainly reflective of the differing populations 
used for the studies, and the prevalence of bladder cancer within those populations.  The low end of this 
range, 19.7%, was found in the one study that was of good quality and tested patients in a primary care 
setting (Grossman).  In this case, the PPV would be unacceptably low.  Far too many patients with a 
positive test would have to undergo a full urologic workup, undergoing unnecessary testing and entailing 
significant risk (detailed in key questions 4 and 5), as well as incurring significant financial burden.  NPV 
ranged from 67% to 97%, the latter of which was found in the Grossman study.  The higher end of this 
range would be acceptable for a screening test, as those who test negative could be reasonably assured of 
being free of disease. 
 Similar to the studies identified for hemoglobin dipstick and urine cytology, the overall body of 
evidence for NMP22 is weak.  We identified two good quality studies, which yielded estimates of 
sensitivity that were much too low for screening purposes.  Like the other diagnostic tests examined so 
far, the body of evidence needs to be improved substantially before this test can be recommended for 
screening.  NMP22 does have the advantages of being very easy to perform and a relatively cheap test 
($13.50 per test).  Thus, if well-conducted studies could demonstrate a greater sensitivity, specificity and 
PPV, this would be an attractive candidate for screening. 
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Bladder Tumor Antigen-stat (BTA stat) 
BTA stat (Polymedco, Cortlandt Manor, NY) is an assay that detects human complement factor H-related 
protein (hCFHrp) in the urine (64).  This assay is approved by the US FDA for management of bladder 
cancer in combination with cystoscopy.  It is a point-of-care assay that is performed by placing five drops 
of urine in a sample well, with qualitative results (positive or negative) available within five minutes.  
Cost of the test is low, at $10 per test (56). 
Search results 
Performance of our search for studies of the diagnostic accuracy of BTA stat through MEDLINE, 
EMBASE, and the Cochrane database, in addition to review of reference lists yielded an initial total of 74 
articles.  Of these, we excluded 28 citations that were clearly not related to our study question based on 
title review.  Thus, 46 citations were available for abstract review.  Of these, one was excluded that was 
published solely in abstract form.  On abstract review, 22 studies were excluded that did not meet our 
eligibility criteria.  This left 23 articles for full-text review.   
 Of the 31 articles reviewed in full-text form, 8 were excluded on the basis of being review 
articles.  An additional 11 articles were excluded because they did not meet our eligibility criteria.  
Specifically, three studies were excluded because they did not present enough information to construct a 
2x2 table; these studies reported only sensitivity or specificity, but not both.  Eight further articles were 
excluded because they measured the diagnostic accuracy of BTA stat for recurrent bladder cancer, not 
primary disease.  This left four articles for analysis that met all of our eligibility criteria.  They are 
described in detail below.  Please see figure 5 below for a flow chart of included and excluded articles. 
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Figure 5.  Flow chart of included and excluded articles, Key Question 2, BTA stat 
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Description of included studies 
All four studies that met our eligibility criteria have been included for cytology and NMP22 as well.  
Detailed descriptions of these studies and their quality grades are available above in table 7 and table 8.  
These four studies include three of poor quality and one of good quality (the systematic review by Glas et 
al.).  Briefly, sensitivity of BTA stat for primary bladder cancer detection ranged from 63% to 78%, with 
an estimate of 70% from the systematic review.  Specificity ranged from 69% to 82%, with an estimate of 
75% from the systematic review.  Positive predictive value ranged from 51% to 81%, and negative 
predictive value ranged from 70% to 87%.  Please see table 11 below for a condensed presentation of 
each study‟s estimates of diagnostic accuracy. 
Table 11 – Diagnostic accuracy estimates for BTA stat for included studies 
Reference Bhuiyan 2003 (53) Boman 2002 (54) Glas 2003 (62) Saad 2002 (55) 
Study 
design 
Case-control Case-control Systematic Review Case-control 
Total 
participants, 
N 
233 156 2,290 120 
Sensitivity 76% 78% 70% 63% 
Specificity 69% 75% 75% 82% 
PPV 51% 81%  73% 
NPV 87% 70%  77% 
Overall 
study 
quality 
Poor Poor Good Poor 
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Comments  More sensitive for 
higher grades and 
stages 
  
 
 
Synthesis of the evidence 
Application of our eligibility criteria to the search results yielded a total of only four studies for analysis.  
Estimates of diagnostic accuracy for BTA stat tended to be much less varied than for the other tests 
examined thus far.  Sensitivity ranged from 63% to 78%.  While this may represent a sensitivity that is 
higher than any of hemoglobin dipstick, cytology or NMP22, it is impossible to determine due to the 
small number of studies and overall poor quality of studies.  The one good quality study included, the 
review by Glas, was performed on poor quality studies itself.  If these estimates of sensitivity were taken 
as truth, they would still be too low for screening purposes.  A large number of patients with disease 
would be missed and would experience a false sense of reassurance.  Specificity ranged from 69% to 
81%, which are figures that are likely still too low to recommend BTA stat for screening.  PPV ranged 
from 51% to 81%, figures that are too low and are raised by several factors: the three studies reporting 
PPV were done in high-risk urologic populations and had poor internal validity. 
 Like the other three tests described thus far, the overall body of evidence for the diagnostic 
accuracy of BTA stat for primary bladder cancer diagnosis is weak.  The one good quality study identified 
estimated its sensitivity and specificity at 70% and 75% respectively, numbers that are too low to 
recommend the test for screening purposes.  Like NMP22 and hemoglobin dipstick, BTA stat does have 
several attractive characteristics that would make it well-suited for screening.  It is relatively cheap ($10 
per test) (58), results are available immediately, and it is easy to administer and interpret.  However, the 
body of evidence will have to be substantially improved, and estimates of sensitivity, specificity and PPV 
80 
 
will need to be shown higher before BTA stat could be considered as the sole test in a screening program 
for bladder cancer. 
 
UroVysion FISH 
Bladder cancers frequently exhibit well-defined chromosomal alterations, which can be detected by 
fluorescent in situ hybridization (FISH) assays (64).  UroVysion (Abbott, Des Plaines, IA) is a 
multitarget, multicolor FISH assay using probes that can detect aneuploidy of chromosomes 3, 7, or 17, or 
loss of the 9p21 locus.  UroVysion does require expert pathologist interpretation, and is quite expensive at 
$475 per test (56). 
Search results 
Performance of our search for studies of the diagnostic accuracy of UroVysion FISH through MEDLINE, 
EMBASE, and the Cochrane database, in addition to review of reference lists yielded an initial total of 54 
articles.  Of these, we excluded 23 citations that were clearly not related to our study question based on 
title review.  Thus, 31 citations were available for abstract review.  On abstract review, 17 studies were 
excluded that did not meet our eligibility criteria.  This left 14 articles for full-text review.   
 Of the 14 articles reviewed in full-text form, three were excluded on the basis of being review 
articles.  An additional 10 articles were excluded because they did not meet our eligibility criteria.  
Specifically, one study was excluded because it did not present enough information to construct a 2x2 
table; this study presented only sensitivity, but not specificity.  Nine further articles were excluded 
because they measured the diagnostic accuracy of UroVysion FISH for recurrent bladder cancer, not 
primary disease.  This left one article for analysis that met all of our eligibility criteria.  It is described in 
detail below.  Please see figure 6 below for a flow chart of included and excluded articles. 
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Figure 6.  Flow chart of included and excluded articles, Key Question 2, UroVysion FISH 
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Description of included studies 
After application of our eligibility criteria to the studies obtained through our search, only one study was 
included for analysis.  This study was a case-control conducted by Marin-Aguilera and colleagues, and 
has been described in detail in the section on urine cytology (60).  In brief, this study was conducted in a 
high-risk urologic population, and included several substantial weaknesses, namely a lack of information 
on patient selection, patient demographics, and application of the reference standard to controls.  For 
these reasons, the study was given an overall grade of “poor”.  The sensitivity of UroVysion FISH for 
primary bladder cancer detection was reported as 70.3%.  Specificity was high at 94.7%.  The positive 
predictive value was reported as 98%, and the NPV was reported as 45%. 
Synthesis of the evidence 
Since the only study included for analysis was of poor quality, it is difficult to draw any conclusions 
about the diagnostic accuracy of UroVysion FISH.  Its reported specificity and PPV are very high, and if 
accurate would be well-suited for screening purposes.  However, a sensitivity of 70.3% would be too low, 
as a large number of people with disease would be missed; this is reflected in the similarly low NPV.  
Obviously, it is important that the body of literature be improved before any sort of recommendation 
could be made.  However, even in the hypothetical case that future well-conducted studies show 
acceptable estimates of sensitivity, specificity and PPV, this UroVysion FISH has several characteristics 
that would make its use as a screening modality not feasible.  It is extremely expensive, with a cost per 
test of $475 (56).  Furthermore, it requires expert pathologist interpretation.  The use of UroVysion FISH 
as a screening test may not be possible, even in the presence of positive test characteristics.  We cannot 
recommend the use of UroVysion FISH as a screening modality at this time. 
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ImmunoCyt 
The ImmunoCyt assay (DiagnoCure, Quebec, Candada) uses immunofluorescence technology to detect 
cellular markers of bladder cancer in exfoliated cells from voided urine (64).  The test requires urine 
fixation with ethanol or isopropyl alcohol before shipment to a reference cytopathology laboratory for 
interpretation.  It is FDA approved for use in conjunction with cystoscopy and cytology for the 
management of bladder cancer.  The cost of the test is high, at $358 per test. 
Search results 
Performance of our search for studies of the diagnostic accuracy of ImunoCyt through MEDLINE, 
EMBASE, and the Cochrane database, in addition to review of reference lists yielded an initial total of 38 
articles.  Of these, we excluded 19 citations that were clearly not related to our study question based on 
title review.  Thus, 19 citations were available for abstract review.  On abstract review, 8 studies were 
excluded that did not meet our eligibility criteria.  This left 11 articles for full-text review.   
 Of the 11 articles reviewed in full-text form, all 11 were excluded because they did not meet our 
eligibility criteria.  Specifically, one study was excluded because it did not present enough information to 
construct a 2x2 table; this study presented only sensitivity.  Ten further articles were excluded because 
they measured the diagnostic accuracy of ImmunoCyt for recurrent bladder cancer, not primary disease.  
This left no articles for analysis that met all of our eligibility criteria.  Please see figure 7 below for a flow 
chart of included and excluded articles. 
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Figure 7.  Flow chart of included and excluded studies, Key Question 2, ImmunoCyt 
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Synthesis of the evidence 
We identified no articles that met our eligibility criteria regarding the use of ImmunoCyt as a detection 
test for primary bladder cancer.  Therefore, we cannot speculate on its sensitivity, specificity, positive 
predictive value, or negative predictive value.  ImmunoCyt is very expensive, with a cost per slide of 
$130 and a suggested retail price of $358 per test.  Furthermore, the use of this test requires expert 
pathologist interpretation.  Clearly, with no data on its performance characteristics, in combination with 
its prohibitively high price and difficulty of administration, we cannot recommend the use of ImmunoCyt 
as a screening test for primary bladder cancer at this time. 
 
Key Question 3 
Search Results 
Performance of our search for studies of immediate treatment of early-stage bladder cancers versus 
expectant management through MEDLINE, EMBASE, and the Cochrane database, in addition to review 
of reference lists yielded an initial total of 84 articles.  Of these, we excluded 51 citations that were 
clearly not related to our study question based on title review.  Thus, 33 citations were available for 
abstract review.  On abstract review, 17 studies were excluded that did not meet our eligibility criteria, 
and one was published only in abstract form.  This left 15 articles for full-text review.   
 Of the 15 articles reviewed in full-text form, all 15 were excluded because they did not meet our 
eligibility criteria.  Four were found to be review articles on treatment delay of invasive bladder cancer.  
Nine articles reported survival as a function of the delay of cystectomy for invasive disease.  One article 
that may have been included, reporting survival as a function of various pre-treatment delays according to 
initial tumor stage, was excluded because stage T2 tumors were included in the same category as T1 
tumors (our severity of interest).  Finally, one study that did report results of expectant management of 
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early-stage tumors was excluded because all cases were recurrent, not primary tumors.  Additionally, 
there was no comparison group included in this study.  This left no articles for analysis that met all of our 
eligibility criteria.  Please see figure 8 below for a flow chart of included and excluded articles. 
 
Figure 8.  Flow chart of included and excluded studies, Key Question 3 
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Synthesis of the evidence 
Through our search of the literature, we were not able to identify any studies that compared outcomes for 
immediate treatment versus expectant management for those with early-stage bladder cancer.  Answering 
this question is essential for the recommendation of a screening program; if expectant management of the 
early-stage tumors that screening would discover does not result in better outcomes than immediate 
treatment, then screening may not be beneficial.   
One study came close to being included, and may help us get an idea of the natural history of 
these small tumors.  In a 2003 retrospective cohort study, Soloway and colleagues present long-term 
outcomes of 32 patients that were followed with observation only (65).  All patients included had a 
history of Ta or T1 transitional cell carcinoma of the bladder.  Upon cystoscopy, they were observed to 
have small, papillary, and low grade-appearing tumors.  On this basis, the patients entered an observation 
period, as opposed to undergoing immediate transurethral resection of their bladder tumor (TURBT).  
Patients received cystoscopy every 3 to 5 months thereafter.  The observation period ended if the patient 
needed to have the tumor resected or fulgurated, or if the tumor was not longer apparent (8 tumors 
disappeared during the observation).  The mean observation period was 10 months.  The average tumor 
growth was 1.77 mm per month.  No tumors progressed to muscle invasion during observation periods.  
The study was ultimately excluded because it was conducted entirely among patients with a history of 
bladder cancer, and thus all tumors detected were recurrent.  Additionally, there was no comparison group 
of patients presented that did undergo immediate treatment. 
The study by Soloway and colleagues shows that a delay in treatment of the early-stage tumors 
that would be picked up by screening may not have a significant effect on morbidity.  However, we 
cannot draw many conclusions from this study, as there was no comparison group, and it dealt entirely 
with bladder tumor recurrences as opposed to primary disease.  A randomized trial, wherein patients with 
early stage disease are randomized to immediate treatment or observation, would be the best evidence to 
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answer the question, “Does earlier treatment lead to reduced morbidity and mortality?”  Answering this 
question is essential to the recommendation of a screening program.  Currently, we have insufficient 
evidence to answer this question. 
 
Key Question 4 
Search Results 
Performance of our search for screening trials that reported harms through MEDLINE, EMBASE, and the 
Cochrane database, in addition to review of reference lists yielded an initial total of 222 articles.  Of 
these, we excluded 142 citations.  The majority of these exclusions were done on the basis of title review, 
as they were clearly not related to our study question.  125 of the 222 initial citations were excluded in 
this manner, leaving 97 citations for abstract review.  Of the 97 abstracts up for review, 16 were excluded 
because they were only published in abstract form.  Another two abstracts were excluded because we 
were unable to retrieve the full text; however, these articles would also have been excluded in the abstract 
review on the basis of failing to answer our key question (33, 34).  On abstract review, a further 17 
articles were excluded as the studies clearly did not meet eligibility criteria.  This left 62 articles for full-
text review.   
Of the 62 articles reviewed in full-text form, 46 were review articles on the subject of screening 
for bladder cancer, and were thus excluded.  The remaining 16 articles all reported data from actual 
screening trials.  All sixteen of these articles were excluded because none of them reported harms of 
screening as an outcome.  See figure 9 below for a flow chart of included and excluded articles. 
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Figure 9.  Flow chart of included and excluded studies, Key Question 4 
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Synthesis of the evidence 
Unfortunately, our search of the literature did not identify any screening trials that reported harms of 
screening as an outcome.  This was to be expected of the six trials that were excluded in full-text review 
in key question one, as they merely reported the tumor characteristics of tumors identified with their 
screening protocol, as opposed to any sort of long-term outcomes.  However, it was hoped that the two 
studies by Messing and Britton on hematuria home screening would have reported some form of harms 
data.  They did not do so, and in fact long-term outcomes, in this case mortality, are only reported (in both 
studies) for the group of patients that were diagnosed with bladder cancer during the initial screening 
period, as opposed to the screened cohort as a whole. 
 When trying to do decide whether or not to implement a widespread screening program, it is 
essential that both the benefits and the harms of such a program are detailed.  This is the only way in 
which we can make an informed decision.  By balancing the harms and benefits, we can decide whether 
screening is worth the time and monetary expenses involved.  It is our hope that a large, randomized 
controlled trial is performed sometime in the near future, reporting long-term morbidity and mortality 
outcomes.  Additionally, it is essential that this trial also report estimates of overdiagnosis, unnecessary 
treatment, and psychological harms.  Until then, we are left without a key piece of the equation for 
deciding whether or not to screen asymptomatic patients for bladder cancer. 
 
Key Question 5 
Search Results 
Performance of our search for studies reporting harms of cystoscopy, CT urography, MR urography, and 
renal ultrasound (RUS) through MEDLINE, EMBASE, and the Cochrane database, in addition to review 
of reference lists yielded an initial total of 506 articles.  Of these, we excluded 424 citations that were 
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clearly not related to our study question based on title review.  Thus, 82 citations were available for 
abstract review.  On abstract review, 44 studies were excluded that did not meet our eligibility criteria, 
and one was published only in abstract form.  This left 38 articles for full-text review.   
 Of the 15 articles reviewed in full-text form, 32 because they did not meet our eligibility criteria.  
Ten were found to be review or background articles on the performance of various radiological 
techniques.  Four articles were excluded that compared patient preferences between flexible cystoscopy 
and rigid cystoscopy, but did not report rates of harms for either.  Eight studies were excluded that were 
concerned with the development of contrast-induced nephropathy, but were not limited to CT or MR 
urography.  Ten articles were concerned with describing new uses of CT and MR in general, and were 
thus excluded.  No articles were found detailing harm of renal ultrasound.  This left six articles for 
analysis that met all of our eligibility criteria, all of which detailed various harms of cystoscopy, the 
diagnostic modality of choice for cancer of the lower urinary system (bladder).  Please see figure 10 
below for a flow chart of included and excluded articles. 
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Figure 10.  Flow chart of included and excluded studies, Key Question 5 
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Description of included studies 
In a 2000 study, Almallah and colleagues used a case series design to prospectively evaluate 103 patients 
seen as outpatients for flexible cystoscopy (66).  Primary outcomes for this study were the development 
of urinary tract infection and the experience of UTI symptoms.  Patients were taken in a non-consecutive 
manner, and the authors do not report what criteria was used to include patients; they were receiving 
cystoscopy for a variety of indications.  Patients were excluded if they had pyuria preceding the 
cystoscopy.  Mean age of the participants was 56, and the group consisted of 63 male and 40 females.  
Midstream urine samples were provided 48 hours after the procedure for urinalysis, and patients 
concurrently answered self-administered questionnaires for the ascertainment of symptoms.  Of the 
sample of 103 patients, 5 (4.8%) were found to have developed bacteriuria at 48 hours post-cystoscopy.  
Additionally, 12 patients experienced symptoms of UTI.  We gave this study a grade of “fair” for its 
internal validity; we do not know on what basis the patients were chosen for participation, introducing 
potential for selection bias.  Measurement of UTI, as defined by bacteriuria consisting of > 10 colony 
forming units per high power field, is likely to be valid and reliable.  We graded the external validity as 
“good”.  The patients seen in this study are likely to be fairly representative of a group of patients that 
would be undergoing cystoscopy after receiving a positive screening test.  The overall grade for this study 
was “fair”, and it gives reasonable evidence that a small subset of patients may experience urinary tract 
infection following cystoscopy, and a small percentage more will experience UTI-like symptoms. 
 In a 2002 study, Burke and colleagues used a case series design to examine 420 consecutive 
patients presenting for flexible cystoscopy (67).  Their primary outcomes included pain level during the 
procedure, development of UTI, visits to the patients‟ general practitioner post-procedure, and the 
experience of UTI symptoms.  Mean age of the patients was 66, with 297 men and 95 women receiving 
cystoscopy for a variety of reasons.  Pain was measured on a linear analogue scale (1-10) immediately 
following the procedure.  Symptoms were measured by way of a questionnaire returned 7 days after the 
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procedure.  The final 110 patients (out of 420) were asked to present to the urology department three days 
after their procedure, where they provided a midstream urine sample for urinalysis.  Their definition of 
UTI was > 10 c.f.u/hpf, with a pyuria of > 10 white cells per high power microscopy field.  392 out of 
420 patients returned their questionnaire.  After tabulation of the answers, the median overall pain score 
during the procedure was 1.1 (out of 10).  19% of patients experienced frank hematuria, 49.5% 
experienced pain on voiding, and 37% experienced urinary frequency.  After 48 hours these figures had 
decreased to 3%, 6% and 12.5%, respectively.  Of the patients who were not instructed to return for a 
urine sample, 7% contacted their general practitioner, and 6% received a prescription for antibiotics.  3% 
of those who presented for a urinalysis had cystoscopy-induced UTI.   
We gave the internal validity of this study a grade of “fair”.  A consecutive selection of patients 
was used, and each received the same procedure.  However, results may have differed in those who 
returned their questionnaires versus those who did not.  It is difficult to speculate which way this would 
bias the results – it is possible that those who returned their questionnaires had a higher rate of UTI and 
symptoms, or it is possible that they had a lower rate.  In reality, the two groups likely did not differ, and 
the results were not biased.  Similarly, there is a chance that those chosen to receive a urinalysis 3 days 
post-cystoscopy differed from those who did not, but it is not likely that the last 110 patients differed 
substantially from the first 310.  External validity was good, as there was a wide spectrum of patients 
included that would be similar to the population identified by screening.  Overall study grade is good.  
The patients in this study experienced a higher degree of UTI symptoms than those in the Almallah study; 
however, these symptoms were transient and mostly decreased by 48 hours.  Pain during the procedure 
does not appear to have been substantial.  3% of those who returned for urinalysis had confirmed UTI, a 
figure that is slightly lower than those reported by Almallah, perhaps due to their more stringent 
definition of UTI (including a white cell count). 
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In 1990, Clark and colleagues reported results of a case series aimed at quantifying urinary tract 
infection in 161 consecutive patients that received cystoscopy in an outpatient setting (68).  124 males 
and 37 females were included, but other demographic data was not reported.  Patients were receiving 
cystoscopy for a variety of indications.  Midstream urine samples were collected immediately before and 
three days after the procedure.  UTI was defined as > 10^5 organisms / milliliter.  Of note, 29 samples 
were excluded from analysis.  Eight were found to be infected prior to cystoscopy, and 21 of the post-
procedure samples were unavailable due to the patients failing to provide a specimen.  Of the final group 
of evaluable samples, 7.5% (12 patients) showed UTI.  However, if a more stringent definition of UTI 
were used (wherein pyuria > 10 WBC per high powered field is a criterion), only 1.9% of the sample 
would have been diagnosed with UTI.  We gave the internal validity of this study a grade of “fair”.  We 
are not given much in the way of information about the patients, and several failed to provide an adequate 
sample for measurement.  However, a consecutive sample of patients was used, and the measurement of 
UTI by urinalysis is valid.  External validity was given a grade of “good”, as the population once again 
was similar to a positive-screening population.  Overall study quality was “fair”.  This study, like those by 
Almallah and Burke, showed that a small percentage of patients may experience urinary tract infection 
after cystoscopy. 
In a similar study to those reported thus far, Denholm and colleagues reported the results of a case 
series of 100 consecutive patients undergoing flexible cystoscopy in 1990 (69).  Information on these 
patients was limited, as the authors did not report a mean age or gender distribution.  Primary outcomes 
consisted of the presence of dysuria, frequency, hematuria, feeling unwell, and visits to their family 
doctor.  All patients were questioned immediately after the procedure on their tolerance of it, and they 
were also given a questionnaire to fill out and return one week later.  98 of the 100 patients returned the 
questionnaire.  The authors found that 89% of the patients found the procedure painless, and 11% 
experienced some pain as the scope passed through the external urethral sphincter.  In the post-procedure 
period, 21% experienced dysuria, 14% experienced urinary frequency, 6% had frank hematuria, 8% felt 
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unwell, and 2% consulted their family doctor.  Internal validity for this study was rated as “fair”; there is 
not much information about the patients presented, but they were not likely to have significantly differed 
from the populations included in the other studies analyzed thus far.  Almost all of the patients returned 
their questionnaires.  External validity was also rated as “fair”, for although we do not know the 
characteristics of the population we can infer that they would be reasonably similar to a screened 
population.  Overall study quality was fair.  Again, we see here that cystoscopy can lead to a small 
percentage of patients experiencing symptoms of UTI. 
In 2009, Matin and colleagues enrolled 554 consecutive patients in a prospective case series 
looking at harms incurred during the actual performance of cystoscopy (70).  Information on patient 
demographics is again limited, although the authors do mention that they were receiving cystoscopy for 
the full spectrum of urologic indications.  The primary outcome was “patient events”, defined loosely as 
any adverse event that occurred during the performance of the procedure.  A nurse documented all such 
events in the patient‟s chart.  After all cystoscopies had been performed, only one patient (0.18%) had a 
patient event.  This patient experienced a possible vasovagal response.  No patients experienced bleeding, 
perforation, or a major cardiopulmonary event.  The internal validity of this study was reported as “fair”.  
There is not information on the demographics of the population; however, there is no reason to believe 
that this population would inherently experience any more or less adverse events than other populations.  
Recording of such events was likely done in a reliable manner by the nurses.  Furthermore, patient 
selection was consecutive.  External validity was also rated as “fair”, since we do not know the 
characteristics of the population.  Overall study quality was fair.  This study does demonstrate that the 
performance of cystoscopy is likely reasonably safe. 
In a 2004 study, Stav and colleagues measured a variety of quality of life outcomes in 108 
consecutive patients referred for diagnostic cystoscopy (71).  Mean age of these patients was 67, with 78 
men and 22 women.  The primary outcomes consisted of pre-treatment anxiety, pain, adverse events, 
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sexual performance, and quality of life.  A number of different validated instruments were used to 
measure these outcomes.  Quality of life was measured by way of the SF-36 short-form health survey.  
BPH-like symptoms were measured with the IPSS (international prostate symptom scale), and sexual 
function was measured with the EDIS, or erectile dysfunction impact scale.  These three questionnaires 
were administered before cystoscopy, and 2, 14 and 30 days after.  Pre-treatment anxiety was measured 
with a visual analogue scale from 0 (none) to 5 (maximal).  Pain was measured with a similar visual 
analogue scale immediately after the procedure as well as 1, 2, and 14 days after.  Adverse events were 
assessed 14 days post-procedure.   
Results showed that pre-procedure anxiety was moderate, at a mean of 2.01 on a scale from 0 to 
5.  Pain was minimal, with an average of 1.41 (on a 0 to 5 scale) immediately after the treatment, and 
dropping to 0.51 by two days.  96% of patients reported it was less than or as painful as they had 
expected.  Results from the SF-36 questionnaire testing quality of life scores did not differ significantly 
before and after the procedure, with a mean of 15.97 (out of 36) before and 16.04 after.  Sexual function 
did suffer in the immediate post-procedure period.  Scores on the EDIS averaged 15.61 before 
cystoscopy, but the mean was 9.26 two weeks after.  This instrument is on a 5-25 scale, with lower 
numbers representing greater erectile dysfunction.  9.26 falls in the “severe” range of 5-10.  The mean 
EDIS score did go back to baseline one month after the procedure.  55% of sexually active patients 
experienced a decline in libido two weeks after, and 76.5% reported impaired satisfaction from sexual 
relations at the same time.  Both of these figures returned to baseline at one month.  Finally, the results for 
UTI symptoms are as follows: 11% experienced dysuria, 7% experienced urethrorrhagia, 2% had 
bacteriuria, and none had fever or urinary retention. 
We gave the internal validity of this study a grade of “good”.  A consecutive sample of patients 
was included, and measurement of the various outcomes was performed with validated, reliable 
instruments.  Furthermore, almost all of the patients (104 out of 108) returned their questionnaires at all 
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time points.  We also gave the external validity a grade of “good”, as patient demographics were reported 
and were similar to those expected from a screened population.  Overall study quality was good.  This 
study shows that while cystoscopy may not produce large amounts of pain, it does produce some sexual 
side effects that can last up to a few weeks.  UTI symptoms were once again present in a small percentage 
of patients. 
Synthesis of the evidence 
Performance of our search yielded six articles meeting our eligibility criteria for cystoscopy.  From these 
studies, we learned that cystoscopy as a whole is a relatively safe procedure, with a small number of well-
defined transient adverse effects that can occur in the immediate post-procedure period.  Incidence of 
urinary tract infection following cystoscopy ranged from 3% to 7.5% in these studies, with the latter 
figure coming from a study that used a less stringent definition of UTI.  The presence of UTI-like 
symptoms ranged from 11% to 49.5%, with most symptoms returning to baseline within a few days.  
Thus, a minority of patients may experience UTI symptoms after cystoscopy, but only a small subset of 
these patients will actually have an infection.  An important finding from the Stav study was the presence 
of sexual side effects.  A significant number of their patients experienced worsening of their erectile 
dysfunction and dissatisfaction with their sexual relations, both of which returned to baseline by one 
month after the procedure.  Another important finding of these studies is that the actual performance of 
the procedure does not entail a great deal of risk.  The strength of evidence of the included studies is 
reasonable.  We can be fairly sure that they are accurately representing the harms of this invasive 
procedure. 
 While we did not identify any studies concerning the harms of CT urography, MR urography or 
renal ultrasound, a brief examination of some of the articles we excluded can facilitate a qualitative 
understanding of the risks involved.  CT urography has recently become the imaging modality of choice 
in the diagnosis of bladder cancer, largely replacing the more traditional excretory urography (IVP) (72).  
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It has the advantage of combining helical tomographic imaging with imaging during the renal excretory 
phase, and is able to visualize the entire urinary system in one scan.  Harms due to CT in general can be 
broken down into two categories: exposure to radiation, and adverse reactions to contrast material.  CT 
urography does represent a large increase in radiation dose over conventional IVP.  As a function of the 
number of phases included and the range of the scans, effective dose values vary from 16 to 32 mSv (73, 
74).  This is comparable to the background radiation a human might experience in 5 to 9.5 years.  By 
comparison, IVP gives an effective dose of radiation of 3 mSv, and a chest x-ray gives an effective dose 
of only 0.1 mSv (75).  Of course, any exposure to radiation does entail some risk for the development of 
cancer. 
 The other major category of harm due to computed tomography is comprised of adverse reactions 
to contrast material.  Contrast-induced nephropathy (CIN) is a known complication of intravenous, 
iodinated contrast, and is a common cause of renal failure.  This risk is increased in those with pre-
existing renal insufficiency or diabetes (76).  In one of our excluded studies, Mitchell and colleagues 
prospectively enrolled 664 patients who received intravenous contrast for a contrast-enhanced CT at 
Carolinas Medical Center in Charlotte, NC (76).  The primary outcome of this study was CIN, as 
measured by an increase in serum creatinine of greater than 0.5 mg/dl or greater than 25% within 2 to 7 
days of contrast administration.  In their sample, a total of 11% (n=70) of patients developed CIN, 9% of 
whom (six patients) subsequently developed severe renal failure.  This relatively high number indicates 
that the risk of CIN from contrast-enhanced CT is not trivial.  Furthermore, contrast agents present a risk 
of anaphylactoid reactions as well.  In a recent systematic review (one of our excluded studies), Cochran 
found that the overall risk for adverse reaction is 4% to 12% with ionic contrast and 1% to 3% with 
nonionic contrast (77).  The risk of severe adverse reaction was 0.16% with ionic contrast and 0.03% with 
nonionic contrast.  Thus, while the risks of CT urography in particular have not been studied, the overall 
expected risks include a large radiation dose and possible reactions to contrast material, including CIN 
and anaphylactoid reactions. 
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 MR urography offers several distinct advantages over CT urography.  Magnetic resonance 
imaging does not deliver a dose of radiation, which is one large advantage.  Additionally, the contrast 
agents used in MR (primarily chelates of gadolinium) are generally safer than the iodinated materials used 
in x-rays or CT (78).  In one of our excluded studies, Murphy and colleagues retrospectively reviewed 
patient records of 21,000 patients who received gadolinium contrast media (78).  Of these, 36 (0.17%) 
developed an adverse reaction, 2 of which (0.01%) were severe reactions.  This figure is far lower than 
that reported for the ionic contrast materials of CT, and slightly lower than nonionic contrast (77).  One 
distinct harm of MR is a possible association with the development of nephrogenic systemic fibrosis 
(NSF) in those with advanced renal insufficiency (79).  NSF is a scleroderma-like disease of which 
approximately 200 cases have been reported worldwide thus far.  A causal link between gadolinium and 
this disease has not been established.  Finally, MR offers the significant disadvantage of being more 
expensive than CT or IVP. 
 For those with contraindications to CT or MR, renal ultrasound is the imaging modality of choice 
in the investigation of bladder cancer (in conjunction with cystoscopy).  Ultrasonography is in a class of 
its own in that it utilizes acoustical radiation, as opposed to electromagnetic or ionizing radiation (80).  
Thus, adverse events from the delivery of these waves are virtually non-existent.  Ultrasonagraphy has 
enjoyed a remarkable safety record; furthermore, expenses are much less than CT or MR.  We were not 
able to identify any studies looking at the harms of renal ultrasound, specifically. 
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Discussion 
Summary 
From our systematic review of the key issues surrounding screening for bladder cancer, we have 
determined that the evidence is not sufficient to recommend screening in an asymptomatic population at 
this time.  For each question that needs to be answered in order to make a recommendation of screening, 
the evidence is either of poor quality (key questions one and two) or entirely lacking (key questions three 
and four).  We identified two studies that conducted a screening trial and reported longitudinal mortality 
data (41-50).  These studies both suffered from a number of methodological flaws, including a lack of 
comparison groups (Britton), the use of inappropriate comparison groups (Messing), small sample sizes, 
small numbers of cancers identified, potential for volunteer bias, and a failure to follow the screened 
cohort as a whole, as opposed to only following those patients diagnosed with cancer.  Perhaps not 
surprisingly for a pair of studies that are both so fraught with potential for error, they came to differing 
conclusions on the benefit of screening.  Britton and colleagues claimed that screening did not have a 
mortality benefit (although there is no comparison group to tell us so), and Messing and colleagues 
claimed that screening did have a mortality benefit, albeit by using a cancer registry as their comparison.  
Thus, even though both studies are weak, they do not reach a consensus.  We are left wondering if a 
screening program can indeed have a benefit on bladder cancer-specific morbidity and/or mortality. 
 In addition to our lack of knowledge on morbidity and mortality, we also found in this review that 
the evidence base on potential tests to be used for screening programs is also very limited.  We identified 
a fair number of studies that met our inclusion criteria for the six tests we chose to examine (hemoglobin 
dipstick, cytology, NMP22, BTA stat, UroVysion FISH and ImmunoCyt).  However, the overall quality 
of evidence available for these tests for their use in the diagnosis of primary bladder cancer is poor.  The 
majority of these studies had significant flaws, including the use of high-risk urologic populations, a 
failure to perform the reference standard on every patient, a failure to adequately describe methods of 
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patient selection, and a lack of independent interpretation of the index test and reference test.  Even when 
taking into account the weak quality of this evidence, the performance characteristics of these tests would 
not be sufficient for screening purposes.  None of the six tests had a combination of sensitivity, 
specificity, and predictive values that would warrant their use for this purpose.  Furthermore, the biases 
present in these studies would be more likely to artificially inflate these performance characteristics.  The 
use of a high-risk urologic population, in which the prevalence of disease would be expected to be 
significantly higher than in the general population, would be expected to artificially inflate estimates of 
diagnostic accuracy.  Positive predictive value will certainly be higher in such a high-prevalence 
population; this phenomenon is demonstrated by the low predictive values reported in the study by 
Grossman and colleagues (57), the only study we identified that was not performed in a high-risk 
population.  Therefore, although the overall quality of evidence with respect to potential screening tests is 
poor, limiting our ability to draw meaningful conclusions, we are not confident that studies performed 
with sound methodology would reveal that these tests have high enough sensitivities, specificities and 
predictive values to recommend their use in screening. 
 We have seen that for the evidence we did manage to identify, the overall quality was poor.  
However, there are still several questions regarding screening for which we have no evidence at all.  For 
screening to be beneficial, earlier treatment of disease must reduce morbidity and mortality more than 
later treatment of disease.  We were unable to identify any studies comparing long-term outcomes 
between groups of patients treated immediately and those treated with expectant management.  It is not 
surprising that such a study does not exist, as the AUA recommends immediate resection and a rigorous 
surveillance schedule for all identified bladder tumors (9).  Finding a group of urologists that would be 
willing to perform a trial of watchful waiting would likely be difficult, as they would be going against the 
guidelines of their specialty‟s most prominent organization.  The one study we identified (and 
subsequently excluded) that did make an attempt at expectant management, performed by Soloway and 
colleagues (65), did not have a comparison group with which to judge the efficacy of the intervention, and 
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did not report long-term morbidity or mortality outcomes.  Further, this study has received some criticism 
in the urological community for its reliance on the investigator‟s ability to “stage” a tumor based on its 
endoscopic appearance, without resecting the tumor and allowing for pathological interpretation. 
 Additionally, this search has shown that we have on evidence on the possible harms of screening.  
As discussed, there are a number of different ways in which screening can be harmful.  First, screening 
entails a significant financial burden, on the health care industry as a whole as well as individuals.   
Second, some tumors identified through screening are bound to be cases of overdiagnosis, wherein the 
cancer would not have manifested clinically within the patient‟s lifetime.  Well-performed screening 
studies would give us an idea of the amount of overdiagnosis that would occur, as would more extensive 
knowledge of the natural history of the disease.  Screening can lead to psychological burden among those 
with false positive results, as well as those with true positive results who are “labeled” with a disease at an 
earlier time in life than if they had been diagnosed clinically.   
Harms can also befall patients from a full urologic workup in the case of a positive screening test.  
We identified several studies of fair quality detailing the harms of cystoscopy; these harms include 
urinary tract infection, UTI-like symptoms, and sexual dysfunction, all of which are transient in nature.  
We were unable to identify studies of harm looking specifically at CT urography, MR urography, or renal 
ultrasound, though.  In general, we know that CT and MR do impose risk, mainly involving heavy doses 
of radiation (CT) and possible adverse reactions to contrast (CT and MR), in addition to their high costs.  
Overall, we have little to no information on the amount of harm that would specifically come from a 
screening program. 
In order to make a proper recommendation on a widespread screening program, we must be able 
to calculate the balance between benefits and harms.  With poor quality evidence on the benefits of such a 
program, and with a complete lack of evidence on the harms of screening, we are currently unable to 
recommend a screening program for bladder cancer. 
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Other Guidelines 
As a reflection of the overall poor quality/lack of evidence on bladder cancer screening, no major 
organization currently recommends screening in asymptomatic adults.  The U.S. Preventive Services Task 
Force published a systematic evidence review of the available literature in 2004, recommending against 
routine screening for bladder cancer in adults (D recommendation) (81).  The authors relied heavily on 
the studies by Messing and colleagues and Britton et al. to evaluate the effectiveness of screening on 
morbidity or mortality and came to the same conclusions as we did: any mortality benefit could have been 
explained by lead-time bias, the small number of cancers in the screened group, and differences between 
the men in the two groups.  Similar to our study, the authors were also unable to find any high-quality 
studies that compared outcomes between treated and untreated groups of early stage cancers.  Finally, the 
task force was unable to find high-quality evidence on the accuracy and reliability of available screening 
tests.  Since 2004, there have been a large number of reviews and editorials published concerning 
screening for bladder cancer; however, this USPSTF review was the last published study performed in a 
truly systematic way that conforms to PRISMA guidelines. 
Other major organizations are in concurrence with the USPSTF and do not recommend routine 
screening for asymptomatic adults.  The National Cancer Institute updated their recommendations in 
2008, also citing the studies by Britton and Messing and concluding that there is insufficient evidence to 
recommend screening for an asymptomatic population (82).  The American Academy of Family 
Physicians similarly recommend against routine screening, citing the systematic review by the USPSTF 
as evidence (83).  The Canadian Task Force on Preventive Health Care also recommended against routine 
screening (84).  Further, they claimed that evidence was insufficient to recommend for or against 
screening in high-risk groups, such as smokers and industry workers.  It should be noted that this task 
force has not updated its recommendations since 1994.  Since that time, several of the reports regarding 
the Messing and Britton studies have been released; however, interpretation of these studies has not 
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changed significantly since their recommendations were released.  Importantly, the American Urological 
Association has released no formal stance on bladder cancer screening.  The organization did convene a 
Best Practice Policy Panel in 2001 to formulate recommendations for the evaluation of patients with 
asymptomatic microhematuria (85).  In this report, the AUA specifically delineates that the purpose of the 
panel is not to offer recommendations regarding routine screening. 
 
Limitations  
As with most studies, this systematic review had several limitations.  In our key questions that 
specifically looked at benefits and harms of screening trials (key questions 1 and 4), we excluded any 
trials that did not have long-term follow-ups reporting mortality or morbidity data.  This led us to exclude 
a number of recent screening trials (33-40) that used such modalities as hemoglobin dipstick, NMP22 and 
the urine-based bladder tumor marker UBC (Urinary Bladder Cancer, not FRA approved for screening).  
Exclusion of these studies gives the impression that there is no ongoing research being conducted 
concerning screening for bladder cancer.  Although these studies have been performed in recent years, 
proving interest in the subject matter, they would have been of little use in answering our key questions.  
All of these studies were essentially performed in the same manner as the two included studies: a small 
group of high-risk patients (men over age 50, smokers in some cases) were screened for bladder cancer 
using an inexpensive marker, and initial numbers and staging of tumors found are reported.  However, 
these studies again are plagued with the same problems in that there is no comparison group, and a small 
number of patients are included.  Thus, they do not offer much information aside from telling us that 
“Test X” is capable of detecting bladder cancer in a high risk group.  We mention them here, though, to 
emphasize that interest in screening asymptomatic populations does exist, and that research is being 
performed in such samples. 
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 Other limitations are inherent in our eligibility criteria.  Systematic reviews are subject to bias in 
that exclusions are sometimes made for pragmatic reasons.  In this review, we limited our studies only to 
those printed in the English language.  It is possible that there may be a number of informative, well-
conducted studies performed in other parts of the world that have only been published in foreign 
languages.  We do not anticipate this being a large source of bias in our study.  Through our analysis of 
the included studies as well as many review articles, we found no evidence of landmark studies that were 
not published in English.   
Another limitation related to our inclusion criteria was the exclusion of studies of diagnostic 
accuracy performed in surveillance studies (key question 2).  A large body of literature studying the 
various urine-based tests does exist, although it is principally concerned with measuring the accuracy of 
these tests for recurrences.  In a conservative assumption, we reasoned that primary bladder cancers and 
recurrent tumors behave differently, and that the various tests would perform differently in these two 
scenarios.  However, it is entirely possible that the diagnostic accuracy of the tests would be similar, 
whether dealing with primary disease or recurrence.  In this case, we would have excluded a large number 
of articles that would better enable us to determine the sensitivity, specificity and predictive values of the 
tests.   
On the other hand, we do not anticipate that these excluded studies would demonstrate that the 
tests have acceptable performance characteristics for screening purposes.  One of our excluded studies 
was a good quality systematic review performed by Lotan and colleagues (21).  The authors performed a 
systematic search, and their reporting of results conformed to PRISMA standards.  They did include 
studies of both primary cancer and recurrences, and for this reason we excluded the study.  Using 
hierarchical Bayesian meta-analyses, the authors were able to report pooled estimates for sensitivity and 
specificity.  Like our results, none of the six tests had a high enough combination of sensitivity and 
specificity to be used for screening.  The most specific test was cytology (99%), but its sensitivity was 
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only 34%.  The most sensitive study was NMP22 at 73%, which is still far too low for screening.  Thus, 
even if well-conducted studies of recurrence had been included, it is not likely that they would have 
changed our overall conclusions. 
The final limitations of this review have to do with the quality of the included studies.  Overall, 
the quality of the studies we identified was poor.  This led us to be unable to draw any firm conclusions 
on the benefits or harms of screening, and thus unable to recommend a screening program.  Estimates of 
the performance characteristics of the various tests that were reported in our included studies cannot be 
extrapolated to our target population of asymptomatic primary care patients, and thus these estimates are 
essentially useless.  Furthermore, we wished to present an economic analysis of screening.  Even if 
screening does provide some degree of benefit, it is not likely to be feasible if the cost of the program is 
prohibitively expensive.  However, we were not able to perform this analysis; a cost-effectiveness 
analysis is not possible without data on the “effectiveness” side. 
 
Limitations of the evidence and implications for practice 
Throughout the course of this manuscript, we have continually described the extensive limitations of the 
evidence.  Studies on the diagnostic accuracy of possible tests, as well as the benefits of screening on 
morbidity or mortality, are small in number and those that do exist are of poor quality.  In light of this, we 
cannot draw any conclusions on the potential effectiveness of screening.  Additionally, we do not have 
any data on the harms of screening, or on the efficacy of earlier versus later treatment.  Clearly, the body 
of evidence is severely limited.   
Because of this lack of evidence, there are no obvious implications for changes in practice.  
General practitioners should certainly not begin screening asymptomatic, possibly high-risk patients.  We 
believe, though, that currently the best public health intervention may simply be primary prevention 
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through smoking cessation counseling.  Patients are becoming better informed on the wide array of health 
problems posed by heavy smoking, and yet bladder cancer is one consequence that is not emphasized due 
to its relatively low prevalence.  Counseling strategies should be modified to incorporate some amount of 
education on the risk for bladder cancer.   
Implications for research 
Based on the overall lack of evidence, there is a clear need for a wide-scale, large, prospective, 
randomized controlled trial on screening for bladder cancer.  With this in mind, we wish to give a general 
description of how such a study would be run.  Participants would be randomized into two groups: those 
invited to screen, and those followed with usual care.  The study would be powered for a primary end-
point of bladder cancer-specific mortality.  Secondary outcomes would include bladder cancer incidence, 
tumor grades and stages, amount of testing received, quality of life measures, and total costs of care.  
Sample sizes for this trial would necessarily be very large, both in order to capture an adequate number of 
bladder cancers, and to have the power to detect a clinically significant decrease in morbidity or mortality.  
Sample sizes in previous screening trials have ranged from 44,000 total participants in the Edinburgh 
Randomised Trial of Breast Cancer Screening in 1978 (86), to over 160,000 in the European Randomised 
Screening for Prostate Cancer (ERSPC) trial (87).  Using the formula given by Cassagrande, Pike and 
Smith for calculation of sample sizes (88), our study would require over 44,000 subjects in both the study 
group and control group to show a 25% reduction in mortality (assuming a two-sided alpha level of 0.05 
and a power of 0.8).   
 This screening trial should be limited to participants at high risk for disease, as opposed to 
participants with a wide range of risks, in order to capture a reasonable prevalence of disease and thus 
maximize the positive predictive value of the chosen screening modality.  Our source population will 
consist of men over age 50 who are either current smokers with at least a 10 pack-year history, or former 
smokers with at least a 20 pack-year history.  Exclusion criteria will consist of any history of urothelial 
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cancer, as well as conditions that could predispose to hematuria.  These conditions include benign tumors 
of the urinary tract, known urinary calculi, glomerulonephritis, cyclophosphamide therapy, and subjects 
currently on anticoagulative therapy (Warfarin, Plavix, etc.).  Subjects will be recruited at 10-15 major 
medical centers in distinct geographic areas of the United States on the basis of their age, gender and 
smoking status, over a period of 5-7 years.  Participants will be randomized after informed consent is 
received as close to their screening date as possible, using blocks stratified according to center and age. 
 Subjects will complete a questionnaire at the beginning of the study to determine demographic 
characteristics, medical histories, and screening histories.  Subjects assigned to the screening group will 
have their urine tested with whichever screening modality is chosen, be it hemoglobin dipsticks, NMP22 
or BTA stat (the only three tests that, in our opinion, would be financially feasible).  All participants will 
annual testing, regardless of previous results.  Any positive screening test will result in a full urologic 
work-up, including cystoscopy, urine cytology, and radiographic imaging.  Subjects in both groups will 
be mailed a questionnaire annually.  This questionnaire will contain information regarding screening 
compliance, cancer diagnoses in the past year, and information about quality of life, expenses incurred, 
and follow-up tests performed.  Causes of death will be confirmed through the National Death Index as 
well as death certificates.  Follow-up will continue for 15 years; an independent safety and monitoring 
board will have the power to end the study before this time if data suggests significant overall harm from 
screening.  Statistical analyses will be performed by intention-to-screen. 
 There are numerous barriers to completing this hypothetical study, an admittedly idealized 
scenario.  Our ability to recruit such a large sample size is questionable, particularly given our very 
specific eligibility criteria.  Recruiting 70,000+ men over age 50 for prostate trials such as ERSPC or 
PLCO is presumably much easier than recruiting 70,000+ men over age 50 with a long history of 
smoking.  Furthermore, bladder cancer does not have the same levels of highly visible advocacy as breast 
or prostate cancers, leading to possible ambivalence of potential subjects toward the study.  A trial of this 
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magnitude would also require an extraordinarily large amount of funding, as well as a very long duration 
in order to see any significant effects of screening.  Assuming the trial is able to get off the ground, there 
would certainly be a substantial percentage of the group invited to be screened who would not actually 
comply with screening.  Additionally, a percentage of the control group may be screened.  While general 
practitioners may not specifically screen for bladder cancer, a significant proportion of primary care 
patients receive regular urinalysis for a variety of indications.  In one of our excluded screening trials 
(using NMP22), 73.4% of the screened participants had urinalysis within 3 years before screening (35).  
This makes crossovers a large concern.  Given a long enough period of follow-up, in combination with a 
large enough sample size, an adequate number of bladder cancers would be diagnosed in both groups to 
evaluate for the presence of lead-time or length-time biases. 
 High costs, long duration of the study, and the overall low prevalence of bladder cancer may 
cumulatively decrease the chances of this hypothetical study ever being performed to nil; however, we are 
of the opinion that alternative research designs will not be sufficient to truly show an overall benefit of 
screening.  Since prevalence is relatively low, studies much larger than the ones performed by Messing et 
al. and Britton and colleagues are necessary to produce rates of diagnosis sufficient for comparisons.  
Cohort studies or case-control studies would be feasible if there were a significant number of people 
currently being screened for bladder cancer.  As it stands, almost no one is being intentionally screened, 
and thus comparisons between cases and controls would not differ in terms of screening levels.  Cohorts 
chosen on the basis of screening status would be exceedingly small.  Thus, an RCT may be the only 
feasible way to gain useful information on the effectiveness of screening. 
 In light of the absence of such an RCT currently, in combination with our belief that smoking 
cessation counseling may be the best form of public health intervention, studies showing a beneficial 
effect of smoking cessation on bladder cancer incidence may be helpful.  A retrospective cohort study 
could easily be designed wherein a cohort of smokers is compared to a cohort with similar smoking rates 
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who then quit by a certain date (and were adherent to cessation).  Smoking cessation would have occurred 
15-20 years before analysis.  Data on bladder cancer incidence and mortality would then be collected.  In 
this way, the beneficial effects of smoking cessation on bladder cancer incidence and mortality could be 
evaluated.   
 Finally, there exists a need for further research into earlier versus later treatment of early stage 
bladder tumors.  A randomized trial could feasibly be performed to answer this question.  In such a trial, 
patients with tumors that appear to be low-grade and early stage on cystoscopy would be randomized to 
two groups: one of whom is treated immediately, and the other of whom is treated with expectant 
management.  These two groups of patients would be followed for a number of years, and a wide variety 
of outcomes would be collected.  The primary outcome would be bladder cancer-specific mortality.  
Secondary outcomes would include quality of life indices, bladder cancer-related financial costs, and 
recurrences.  In this way, we would be able to determine whether earlier treatment of the type of tumors 
that would be picked up by screening leads to better outcomes.  If it does not, screening would not be 
effective. 
 
Conclusions 
In a systematic review of the literature, we were able to demonstrate that the evidence is not sufficient to 
recommend screening for bladder cancer in an asymptomatic population.  Two trials of screening have 
been performed that have also reported long-term outcomes.  The two studies came to differing 
conclusions on the mortality benefit of screening; furthermore, both studies suffered from a number of 
significant flaws that prevent us from drawing conclusions.  The body of evidence on the diagnostic 
accuracy of tests used to diagnose primary bladder cancer is similarly weak.  These studies contained 
potential biases that could favorably skew the performance characteristics of the tests.  Even in this case, 
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no single test has a high enough sensitivity and specificity to recommend its use in screening.  Finally, 
there is no evidence on whether earlier treatment of early stage bladder cancer is more beneficial than 
later treatment, and we lack any data on the harms of screening.  Without well-designed studies 
addressing these important questions, we cannot appropriately balance the benefits and harms of a bladder 
cancer screening program.   
 This study highlights the great need for well-conducted research on screening for bladder cancer.  
A wide-spread, randomized controlled trial would be the highest level of evidence available.  As such, we 
recommend a wide-spread trial among older men, using hemoglobin dipstick, NMP22, or BTA stat as a 
screening modality.  It is critical that such a trial collects data on both the benefits and harms of screening, 
so that a balanced evaluation of the screening program can be made.  There is also a need for a 
randomized trial comparing earlier versus later treatment of early stage bladder tumors.  Finally, in the 
absence of high-quality evidence on the effectiveness of screening, we believe that the most effective 
public health intervention for the improvement of the substantial burden of bladder cancer may be 
smoking cessation counseling. 
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Appendix I 
USPSTF-derived quality criteria for internal validity (28) 
Design Criteria 
Randomized controlled trials  Initial assembly of comparable groups 
employs adequate randomization, including 
first concealment and whether potential 
confounders were distributed equally 
among groups. 
 Maintenance of comparable groups 
(includes attrition, crossovers, adherence, 
contamination) 
 Important differential loss to follow-up or 
overall high loss to follow-up 
 Measurements: equal, reliable, and valid 
(includes masking of outcome assessment) 
 Clear definition of the interventions 
 All important outcomes considered 
Case-control studies  Accurate ascertainment of cases 
 Nonbiased selection of cases/controls with 
exclusion criteria applied equally to both 
 Response rate 
 Diagnostic testing procedures applied 
equally to each group 
 Measurement of exposure accurate and 
applied equally to each group 
 Appropriate attention to potential 
confounding variables 
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Cohort Studies  Initial assembly of comparable groups 
employs consideration of potential 
confounders with either restriction or 
measurement for adjustment in the 
analysis; consideration of inception cohorts 
 Maintenance of comparable groups 
(includes attrition, crossovers, adherence, 
contamination) 
 Important differential loss to follow-up or 
overall high loss to follow-up 
 Measurements: equal, reliable, and valid 
(includes masking of outcome assessment) 
 Clear definition of the interventions 
 All important outcomes considered 
 
Appendix II – Evidence Tables for Key Question 1 
Evidence Table I – Descriptive Characteristics 
Reference  
Research design  
Location  
Screening test used  
Frequency of  
testing/Protocol 
 
Recruitment  
Eligibility Criteria  
Total participants, N  
Mean age  
Gender  
Ethnicity  
Duration of follow up  
Invited for screening, N  
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% screened  
Controls, N  
Primary outcome  
Ascertainment of 
outcome 
 
 
Evidence Table II – Study Quality 
Reference  
Randomization  
Allocation concealed?  
Initial Comparability of 
groups 
 
Loss to follow up  
Crossovers  
Drop outs  
Potential for selection 
bias (low, moderate, 
high) 
 
Outcomes assessor 
blinded? 
 
Care provider blinded?  
Equality, reliability and 
validity of outcome 
measurement 
 
Potential for 
measurement bias (low, 
moderate, high) 
 
Important confounders 
measured 
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Potential for confounding 
(low, medium, high) 
 
Analysis: adjustment for 
confounders, intention to 
treat 
 
Overall internal validity 
grade (good, fair, poor) 
 
Generalizability of 
population 
 
Generalizability of 
setting 
 
Generalizability of 
screening test 
 
Overall external validity 
grade (good, fair, poor) 
 
Overall study quality 
grade (good, fair, poor) 
 
Conflicts of 
Interest/Comments 
 
 
Table III – Results 
Reference  
Invited for screening, N  
Screened, N  
% Screened  
Bladder cancer found in 
screened, N (%) 
 
Bladder cancer found in 
controls, N (%) 
 
Controls, N  
Mean duration of follow up  
123 
 
Bladder cancer-specific 
mortality 
- Screened 
- Controls 
- OR/RR (95% 
Confidence 
interval) 
 
All-cause mortality 
- Screened 
- Controls 
- OR/RR (95% 
Confidence 
interval) 
 
Morbidity 
- DALYs 
- QALYs 
- Recurrence 
 
 
 
Appendix III  
USPSTF-derived quality criteria for internal validity of studies of diagnostic accuracy 
Design Criteria 
Diagnostic Accuracy Studies  Screening test relevant, available for primary care, adequately 
described 
 Study uses a credible reference standard, performed regardless 
of test results 
 Reference standard interpreted independently of screening test 
 Handles indeterminate results in a reasonable manner 
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 Spectrum of patients included in study 
 Sample size 
 Administration of reliable screening test 
 
 
Appendix IV – Evidence Tables for Key Question 2 
Table 1 – Descriptive characteristics 
Reference  
Index Test  
Reference Standard  
Location  
Setting  
Total Participants, N  
Mean age  
Gender  
% Grade 1 (WHO 
classification) 
 
% Grade 2  
% Grade 3  
Controls (urological patients, 
other patients, or both) 
 
Cutoff used  
 
Table 2 – Study Quality 
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Reference  
Index test  
Reference standard always performed?  
Duration between index test and 
reference standard 
 
Test interpretation blinded?  
Wide spectrum of patients?  
Sufficient description of test protocol  
Indeterminate results handled in a 
reasonable manner? 
 
Industry sponsorship  
Overall internal validity grade (good, 
fair, poor) 
 
Similarity of study population to 
primary care population 
 
Availability of test  
Ease of administration  
Cost of testing  
Overall external validity grade (good, 
fair, poor) 
 
Overall study grade (good, fair, poor)  
 
Table 3 – Results 
Reference  
Index Test  
Cutoff  
Total participants, N  
% True positives  
% False positives  
126 
 
% False negatives  
% True negatives  
Sensitivity  
Specificity  
Positive Predictive Value  
Negative Predictive Value  
 
Table 3 – Evidence table for Systematic Reviews and/or Meta-analyses 
Reference  
Year  
Location  
Funding  
Design (SR and/or meta-analysis)  
Aims of review  
Study designs included  
Time period covered  
Characteristics of included studies  
Characteristics of included 
populations 
 
Characteristics of interventions  
Main results  
Adverse events  
Was the SR based on a focused 
clinical question? 
 
Was a comprehensive literature 
search strategy used? 
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Did the SR use a standard method 
of to appraise the internal validity of 
included studies? 
 
Was publication bias assessed?  
Did the SR assess and explain 
heterogeneity? 
 
Was the statistical analysis 
appropriate? 
 
Quality rating (good, fair, poor)  
 
Appendix V – Evidence tables for Key Question 3 
Table 1 – Descriptive Characteristics 
Reference  
Research design  
Location  
Setting  
Total Participants, N  
Intervention arm, N  
Controls, N  
Mean age  
Gender  
Ethnicity  
Treatment used  
Handling of control group (interval 
before treatment) 
 
Duration of follow up  
Primary Outcome  
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Ascertainment of outcome  
 
Table 2 – Study Quality 
Reference  
Randomization  
Allocation concealed?  
Initial Comparability of groups  
Loss to follow up  
Crossovers  
Drop outs  
Potential for selection bias (low, moderate, high)  
Outcomes assessor blinded?  
Care provider blinded?  
Equality, reliability and validity of outcome 
measurement 
 
Potential for measurement bias (low, moderate, 
high) 
 
Important confounders measured  
Potential for confounding (low, medium, high)  
Analysis: adjustment for confounders, intention 
to treat 
 
Overall internal validity grade (good, fair, poor)  
Generalizability of population  
Generalizability of setting  
Overall external validity grade (good, fair, poor)  
Overall study quality grade (good, fair, poor)  
Comments  
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Table 3 – Results 
 
Reference  
Intervention arm, N  
Controls, N  
Mean duration of follow up  
Bladder cancer-specific mortality 
- Screened 
- Controls 
- OR/RR (95% Confidence 
interval) 
 
All-cause mortality 
- Screened 
- Controls 
- OR/RR (95% Confidence 
interval) 
 
Morbidity 
- DALYs 
- QALYs 
- Recurrence 
- Other 
 
 
 
Appendix VI: Evidence Tables for Key Question 4 
 
Table 1 – Descriptive Characteristics 
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Reference  
Research design  
Location  
Screening test used  
Frequency of  testing  
Recruitment  
Total participants, N  
Mean age  
Gender  
Ethnicity  
Duration of follow up  
Invited for screening, N  
% screened  
Controls, N  
Primary outcome  
Ascertainment of 
outcome 
 
 
 
Table 2 – Study Quality 
Reference  
Randomization  
Allocation concealed?  
Initial Comparability of 
groups 
 
Loss to follow up  
Crossovers  
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Drop outs  
Potential for selection 
bias (low, moderate, 
high) 
 
Outcomes assessor 
blinded? 
 
Care provider blinded?  
Equality, reliability and 
validity of outcome 
measurement 
 
Potential for 
measurement bias (low, 
moderate, high) 
 
Important confounders 
measured 
 
Potential for confounding 
(low, medium, high) 
 
Analysis: adjustment for 
confounders, intention to 
treat 
 
Overall internal validity 
grade (good, fair, poor) 
 
Generalizability of 
population 
 
Generalizability of 
setting 
 
Generalizability of 
screening test 
 
Overall external validity 
grade (good, fair, poor) 
 
Overall study quality 
grade (good, fair, poor) 
 
Comments  
 
Table 3 – Results 
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Reference  
Intervention arm, N  
Controls, N  
Mean duration of follow up  
Psychological Burden (test used) 
- Screened 
- Controls 
- OR/RR (95% Confidence 
interval) 
 
Unnecessary Testing/Treatment 
- Screened 
- Controls 
- OR/RR (95% Confidence 
interval) 
 
Other indices of harm (specify) 
- Screened 
- Controls 
- OR/RR (95% Confidence 
interval) 
 
 
Appendix VI – Evidence tables for Key Question 5 
 
Table 1 – Descriptive Characteristics 
Reference  
Research design  
Location  
Recruitment  
Total participants, N  
133 
 
Mean age  
Gender  
Ethnicity  
Duration of follow up  
Controls, N  
Primary outcome  
Ascertainment of 
outcome 
 
 
 
Table 2 – Study Quality 
Reference  
Randomization  
Allocation concealed?  
Initial Comparability of 
groups 
 
Loss to follow up  
Crossovers  
Drop outs  
Potential for selection 
bias (low, moderate, 
high) 
 
Outcomes assessor 
blinded? 
 
Care provider blinded?  
Equality, reliability and 
validity of outcome 
measurement 
 
Potential for 
measurement bias (low, 
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moderate, high) 
Important confounders 
measured 
 
Potential for confounding 
(low, medium, high) 
 
Analysis: adjustment for 
confounders, intention to 
treat 
 
Overall internal validity 
grade (good, fair, poor) 
 
Generalizability of 
population 
 
Generalizability of 
setting 
 
Generalizability of 
screening test 
 
Overall external validity 
grade (good, fair, poor) 
 
Overall study quality 
grade (good, fair, poor) 
 
Comments  
 
Table 3 – Results 
Reference  
Intervention arm, N  
Controls, N  
Mean duration of follow up  
Harms (specify) 
- Intervention 
- Controls 
- OR/RR (95% Confidence 
interval) 
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